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INTRODUCTION 
Flavonoids are ubiquitously present in the plant kingdom 
(Ho 1992). They are phenolic compounds (Figure 1). The basic 
structure of these compounds consists of two aromatic rings 
linked by a three carbon aliphatic chain which normally has 
been condensed to form a pyran or, less commonly, a furan 
ring. Based on the oxidation state of the aliphatic fragment 
and the position of C ring attached to the B ring, they can be 
subdivided into: flavones, flavanones and isoflavones. 
Flavonoids are ingested in daily quantities of about 1 g 
by humans who eat diets typical of those found in the Western 
world (Kuhnan 1976). They are present in tea, coffee, cereal 
grains, beans and a variety of fruits and vegetables (Huang 
and Ferraro, 1992). Isoflavones are present in large 
quantities (0.2-1.5 mg/g) in soybean foods (Wang and Murphy 
1994), which are almost the only source of isoflavones in the 
American diet (Messina and Barnes, 1991) . 
Although high intake of fruits and vegetables has been 
associated with lower cancer risk (Willett 1994), evidence 
also suggests that higher intake of isoflavones from a soy 
rich diet in eastern Asia is associated with much lower 
incidence of breast, colon and prostate cancer than in those 
who eat a typical Western diet (Adlercreutz et al., 1991 and 
1995). Therefore, understanding the mechanism of potential 
health protective effects by characterizing isoflavone 
bioavailability and specific cancer-preventive effects is 
important. 
Variety and content of isoflavones in soybean foods 
Soybeans contain three types of isoflavones which are 
present as four chemical forms: 1) the aglycones: daidzein, 
genistein and glycitein; 2) the glucosides: daidzin, genistin 
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and glycitin; 3) the acetylglucosides: 6"-0-acetyldaidzin, 6"-
0-acetylgenistin, 6"-0-acetylglycitin; and 4) the 
malonylglucosides: 6"-0-malonyldaidzin, 6"-O-malonylgenistin, 
6"-0-malonylglycitin (Kudou et al. 1991). 
By high-performance liquid chromatography and photodiode 
array detection, Wang and Murphy (1994) characterized the 
concentration and distribution of all twelve isoflavone 
isomers in 29 commercial soybean foods which were categorized 
into soy ingredients, traditional and second-generation soy 
foods. Compared with unprocessed soybeans (total isoflavone 
concentration: 1.2-4.2 mg/g), high-protein soy ingredients 
such as soy flour and texturized vegetable protein contained 
similar isoflavone concentrations (total isoflavone 
concentration: 1.1-1.4 mg/g), except soy concentrate. Soy 
concentrate was produced by a water or alcohol wash of soy 
flakes to remove soluble carbohydrates and improve 
functionality. It had extremely low isoflavone concentration 
because alcohol washing removed most of the isoflavones. 
With minimal procession soy flour had 6"-0-malonyldaidzin and 
6"-0-malonylgenistin as its major isomer. In contrast, due to 
heat treatment during extrusion processing which transformed 
malonyl isoflavones to acetyl forms, texturized vegetable 
protein had appreciable amount of 6"-0-acetyldaidzin and 6"-0-
acetylgenistin. Traditional soybean foods showed differences 
between nonfermented foods (e.g. tofu) and fermented foods 
(e.g. tempeh). Nonfermented foods had greater levels of 
glucosides, and greater levels of aglycones were present in 
fermented foods due to enzymatic hydrolysis during 
fermentation. Second-generation soy foods such as tofu yogurt 
and tempeh burger were made by adding soy ingredients to a 
variety of foods to replace animal protein and/or to reduce 
fat. They contained only 6-20% of the isoflavones found in 
whole soybeans, since most of the food matrices in these foods 
were nonsoybean constituents. 
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Barnes et al. (1994) examined the extraction of 
isoflavones from several commercial soy foods and ingredients 
with particular reference to the effect of heating during this 
process. Extraction of isoflavones from soy products with 80% 
aqueous methanol at room temperature was just as efficient as 
at 60-80 °C, but extraction at higher temperatures (60-80 °C) 
caused changes in isoflavone composition. To facilitate the 
identification of the isoflavone glycosides in the extracts, 
heated nebulizer-atmospheric pressure chemical ionization (HN-
APCI) and modified electrospray interfaces (ESI) were used to 
introduce the isoflavone conjugates directly from HPLC into 
the mass spectrometer without the necessity of hydrolysis or 
derivatization. They found that soybeans and defatted soy 
flour (which had been minimally heated during their 
extraction) contained mostly isoflavone 6"-0-
malonylglucosides, with lesser quantities of the p-glucosides 
and only trace amounts of 6"-0-acetylglucosides. Soy milk, 
tofu, and soy molasses, each of which are heated to 100 °C 
during their manufacture, contained mostly isoflavone p-
glucosides. Toasted soy flour and an isolated soy protein had 
moderate amounts of each of the isoflavone glycosides. 
In general, variety and content of isoflavones in soy 
foods depend upon their procession such as heat treatment, 
washing, fermentation and dilution by nonsoy ingredients even 
soy foods were made by soy ingredients from same environment 
condition (location and corp year). 
Estrogenic and antiestrogenic effect of isoflavones 
Estrogen is defined as the substance capable of 
stimulating the growth of vagina, uterus and the mammary gland 
and responsible for the development of female secondary sex 
characteristics (Clark et al., 1985) . Weak estrogenic effect 
of isoflavones has been extensively reviewed by Molteni et al. 
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(1995) . 
The estrogen receptor binding affinity of natural and 
synthetic estrogens compared with plant estrogens (mainly 
isoflavones, lignans and flavones) was studied by Shutt and 
Cox (1972) in sheep uterine cytosol. The relative nuclear 
binding affinities in vitro of daidzein, genistein, equol and 
0-desmethylangolensin were only 0.1%, 0.9%, 0.4% and 0.05% of 
estradiol-17p, respectively. However, at high concentrations 
such as 10^-10^ times of estradiol (close to the levels of soy 
isoflavones in human plasma after soybean foods consumption) 
these isoflavones could compete effectively with the 
endogenous mammalian estrogens by competitive inhibition and 
suppress estrogen stimulated growth in mammalian (Adlercreutz 
et al., 1995) . 
In vivo genistein and daidzein are roughly 10^ times less 
effective than estrogens and DES as shown by mice uterine 
enlargement assays (Bickoff et al., 1962). In a uterine 
growth assay reported by Farmakalidis et al. (1985), Inbred 
B6D2F1 mice were assigned to the dose of 0.12 |j,g of 
diethylstilbesterol, 8 mg of genistein or 12 mg each of 
genistin and daidzin in a completely randomized design. The 
testing compounds were suspended in 5% Tween 80 and were 
administered to the mice by stomach intubation in four daily 
doses of 0.1 ml per day. The estrogenic response to 1.5 mg 
of genistein was equivalent to 1 mg of genistein, giving a 1:1 
molar relationship in estrogenic activity between genistin and 
genistein. The estrogenic response to 3.8 mg of daidzin was 
equivalent to 1 mg of genistein. 
Flavonoids may be able to reduce estrogen synthesis. In 
vitro a-naphthoflavone (synthetic flavonoid), chrysin, flavone 
and biochanin A can inhibit the activity of human preadipocyte 
aromatase with IC50 values of 0.5, 4.6, 68 and 113 UM, 
respectively (Campbell and Kurzer, 1993). In another cell 
culture study, isoflavones and their metabolites, daidzein. 
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equol and 0-desmethylangolensin inhibit human placental 
aromatase with ICso of <1 mM, 150 |iM and 160 [iM, respectively 
(Adlercreutz et al., 1993 a). Flavonoids may also decrease 
free estrogens in circulation system through the stimulation 
of sex hormone binding globulin synthesis in the liver. 
Enterolactone (1-10 |1M) can increase sex hormone binding 
globulin synthesis by HepG2 cells in culture (Adlercreutz et 
al., 1991) . 
Isoflavone antiestrogenic activity was also studied in 
neoplastic cells. Verdeal et al. (1980) demonstrated the 
inhibition of binding of [^H]Estradiol to estrogen receptors 
in rat mammary tumors when genistein was added. In addition, 
isoflavones can inhibit the estrogen-receptor complex bind to 
nuclear type II binding site and reduce the estrogen-
stimulated cell proliferation. Daidzein and equol can compete 
with [^H]Estradiol to rat uterine estrogen nuclear type II 
binding sites at ICso of 1 and 9 |IM, respectively (bioflavonoid 
receptor) (Adlercreutz et al., 1992). 
Therefore, weak estrogenic isoflavones from soy food 
consumption most likely exert their antiestrogenic activity 
rather than estrogenic activity to humans. 
Antioxidant activity of isoflavones 
Nairn et al. (197 6) reported that isoflavones inhibited 
lipoxygenase action and prevented peroxidative hemolysis of 
sheep erythrocytes in vitro. Pratt and Birac (197 9) found 
that phenolic compounds in soybeans, defatted soy flour, soy 
protein concentrates and soy isolates have appreciable 
antioxidant activity detected by the rate of p-carotene 
bleaching in a lipid-aqueous system. Rat hepatic cumene 
hydroperoxidase activity was increased significantly after 
feeding a soybean isoflavone extract (at 240 mg isoflavones/kg 
diet) for one week (Hendrich et al. , 1994). 
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In a recent study reported by Wei et al. ( 1 9 9 5 ) ,  effects 
of structurally related flavones and isoflavones on hydrogen 
peroxide (HjOj) production by 12-0-tetradecanonylphorbol-13-
acetate (TPA)-activated HL-60 cells and superoxide anion { O 2 " " )  
generation by xanthine/xanthine oxidase were compared. Among 
the tested flavones and isoflavones at concentrations of 1 0 ,  
50, 100 and 200 |1M, genistein is the most potent inhibitor 
(IC5o= 2 5 |LlM) for TPA-induced H2O2 formation by dimethyl 
sulfoxide differentiated HL -60 cells, daidzein is second ( I C 5 o =  
150 |iM) , and apigenin and biochanin A show little effect. In 
contrast, genistein, apigenin and prunectin are equally potent 
in inhibiting 02'" production (IC5o= 1-2.5 |iM) , with daidzein 
showing a moderate inhibitory effect {IC5o= 5 |lIM) and biochanin 
A exhibiting no effect. 
In an animal study (Wei et al., 1995), dietary feeding of 
250 ppm genistein to 6-7 week old female CD-I mice for 30 days 
significantly enhances the activities of antioxidant enzymes 
including catalase, SOD, GSH-PX and GSSG-R in skin and small 
intestine by 10-30 %. However, no bioavailability data was 
presented, and authors did not compare the effect of genistein 
with other flavones or isoflavones. 
In conclusion, soy isoflavones can act as antioxidants 
directly or indirectly through the enhancement of antioxidant 
enzyme activities. 
Anticarcinogenic effect of isoflavones 
The epidemiologic association between low incidence of 
breast, colon and prostate cancer and high isoflavone intake 
from soy rich diets has been reviewed (Adlercreutz et al., 
1995). Some of their key findings are summarized in later 
part of introduction. In animal studies, feeding a 3 0% 
soybean diet to mouse can protect liver from cancer 
development induced by nitrosamine precursors, dibutylamine 
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and nitrite (Fitzsimons et al. , 1989). Rats consuming a soy-
based diet develop fewer mammary tumors following 
administration of the carcinogens N-methylnitrosourea and 
7 , 12-dimethylbenz[a]-anthracene than rats on isonitrogenous 
and isocaloric diets without soy (Barnes et al., 1990) . In a 
hepatocarcinogenesis model with female F344/N rats initiated 
by 15 mg/kg body wt diethylnitrosamine at 10 days of age and 
promoted by 500 mg/kg diet of phenobarbital, soybean 
isoflavone extract at 240 or 480 mg /kg diet dose levels 
normalized the total hepatic glutathione peroxidase activity 
suppressed by phenobarbital, and inhibited phenobarbital 
promotion as reflected in volume of gama-glutamyltransferase 
and placental glutathione transferase positive altered hepatic 
foci after 3 month of feeding (Lee et al., 1995). 
Genistein inhibits the growth of estrogen receptor-
negative or -positive human breast cancer cell lines 
(concentration for 50% inhibition of cell growth (ICso) =24-44 
|jmol/L; Peterson and Barnes 1991) . Genistein and daidzein 
(ICso of 2.2 |imol/L and 8 ^linol/L respectively) can inhibit 
production of inositol phosphates, key intracellular signals 
of proliferation stimulated by altiminiim tetrafluoride in 3T3 
cells (Higashi and Ogawara 1992) . In addition, inhibition of 
phosphatidyl inositol 4,5-bisphosphate hydrolysis by daidzein 
and genistein may also reduce prostaglandin production and 
further inhibit cell proliferation, since the 2-position on 
the glycerol moiety of PIP2 was usually occupied by 
arachidonic acid. Genistein inhibits the autophosphorylation 
of the epidermal growth factor receptor in the A431 human 
epidermoid carcinoma cells (IC5o= 2.6 |imol/L, Akiyama 1987) and 
DNA topoisomerase II of human leukemic MOLT-4 and HL-60 cells 
(IC5O=31.5 and 48 lOmol/L, respectively) but not the normal 
human proliferating lymphocytes (Traganos et al., 1992) . 
Genistein also blocks endothelial cell proliferation and in 
vitro angiogenesis, another proposed mechanism of 
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anticarcinogenesis (ICso of 5 and 150 |lmol/L respectively, 
Fotsis et al. , 1993). Genistein suppressed TPA-induced 
overexpression of proto-oncogene c-fos, but not c-jun in mice 
fed 250 ppm genistein for 30 days (Wei et al., 1995) . 
These findings suggest that anticarcinogenic activities 
of soy isoflavones are probably due to their profound impact 
on control of cell growth and proliferation at molecular 
levels. Based on our human bioavailability and Wang and 
Murphy's soy food isoflavone data, it seems that only 
isoflavones' normalizing the total hepatic glutathione 
peroxidase activity, suppression of hepatocarcinogenesis, 
phosphatidyl inositol 4,5-bisphosphate (PIP2) hydrolysis and 
proto-oncogene c-fos overexpression at above in vivo and in 
vitro studies may be relevant to the actual isoflavone levels 
in human diet and/or in body general circulation (less or 
equal to 6 and 5.5 [iM for daidzein and genistein, 
respectively) from physiological achievable amounts of soy 
food consumptions (maximum dose we used in human feeding was 
2.7 mg/kg body wt). It is reasonable to propose that a dose 
of soy isoflavones ranging from 1.5 to 2 mg isoflavones/ kg 
body wt per day may exert anticarcinogenic effects in humans 
(Hendrich et al., 1994). 
Modulation of NK cell by flavonoids in cancer prevention 
Natural killer (NK) cells represent a subset of 
lymphocytes (up to 15%) , distinguishable from T and B 
lymphocytes by their morphology, phenotype, and functional 
capability to spontaneously kill tumor or virus-infected cells 
(Whiteside and Herberman, 1989). Morphologically, NK cells 
belong to a subset of large granular lymphocytes; 
phenotypically, they express a characteristic array of surface 
markers (CD3", NKHl* and CDlS") ; and functionally, they can act 
as effector cells that mediate natural immunity, which plays 
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an essential role in immune surveillance against tumors and 
infectious agents. NK cells are not restricted by the major 
histocompatibility complex (MHC) in their function, and they 
are capable of killing a broad range of human solid tumor, 
leukemic, and virus-infected target cells, including cells 
with no detectable MHC expression. 
As reviewed by Whiteside and Herberman (1989), decreased 
natural immunity, as measured in vitro by NK activity and/or 
absolute numbers of circulating NK cells has been found to be 
associated with the development and progression of cancer, 
with acute and chronic viral infections including AIDS, 
chronic fatigue syndrome, psychiatric depression, various 
immunodeficiency syndromes, and certain autoimmune diseases. 
Finlay et al. (1988) proposed that the pronounced 
antitumor effects achieved in vivo against the Lewis Lung 
carcinoma in mice with flavone acetic acid, a synthetic 
flavonoid, was not mediated by direct cytotoxicity, but 
because of its ability to augment natural killer activity. 
This conclusion is based on several pieces of evidence. 
First, the tumoricidal activity of flavone acetic acid was 
more pronounced and occurred more rapidly in vivo than direct 
cytotoxic effects observed in vitro. Second, Lewis lung 
carcinoma cells that were implanted in diffusion chambers in 
the peritoneum of (DBA/6JX C57BL/6J) Fl mice were not 
susceptible to the effects of flavone acetic acid administered 
intraperitoneally. Wiltrout and Hornung (1989) demonstrated 
that a dose of flavone acetic acid (at 220 mg/kg body wt) 
administered intraperitoneally can increase natural killer 
activity in nonlymphoid organs (liver and lung) of (DBA/6Jx 
C57BL/6J) Fl mice as well as in their spleen at 12 h after 
dosing, and that flavone acetic acid plus recombinant 
interleukin 2 (rIL 2) synergistically augmented natural killer 
activity in normal and tumor-bearing mice. 
Soybean isoflavone extracts can significantly increase NK 
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cell activity in rats (Cunnick and Hendrich, unpublished 
data). After rats were fed 240 mg isoflavones/kg diet for 10 
days, liver associated NK cell activity was two fold greater 
than that in the control group. However, rats receiving a 
dose of 480 mg isoflavones/ kg diet did not differ in NK cell 
activity compared with the control group. 
Theoretically, isoflavones acting as antioxidants can 
enhance glutathione peroxidase activity (Hendrich et al., 
1994) which constrains prostaglandin production (Marshall et 
al., 1988). In an interesting study reported by Baxevanis et 
al., 1993), a comparison of natural killer and lymphokine-
activated killer (LAK) cell activity was undertaken in 8 5 
preoperative patients with breast cancer and 75 healthy 
donors. Natural killer cell activity tested in 18-hour 
cultures of effector peripheral blood mononuclear cells with 
K562 or MOLT-4 tumor target cells was significantly diminished 
in these breast cancer patients, and the reduced natural 
killer cell activity was due to abnormally high levels of 
prostaglandin E2 produced by monocytes in culture. It is 
reasonable to hypothesize that soy isoflavones can enhance 
natural killer activity through its inhibition of 
prostaglandin production. However, high levels of genistein 
(20-110 |amol/L) can inhibit tyrosine kinase activity which is 
necessary for the activation of natural killer cells (Borrego 
et al., 1993) . Therefore, the effect of isoflavones on NK 
cell activity may at least depend upon the balance between 
their inhibition of tyrosine kinase activity and suppression 
of prostaglandin production. 
Role of bioavailability in action of health protectants 
Effects of dietary health protectants reqiaire a 
sufficient systemic bioavailability except for those 
substances which can perform their health protective effects 
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at local gastrointestinal tract. Unfortunately, many current 
studies regarding dietary substances' health protective 
effects did not have solid support of bioavailability data. 
From nutritionist point of view, bioavailability of 
dietary health protective substances refers to the proportion 
of these substances absorbed and entered the systemic 
circulation. Except for those had lymphatic vessels as their 
main absorption route, bioavailable health protective 
substances should be not only absorbed but also survived 
first-pass effect which refers to biotransformation by the 
gastrointestinal cells or extraction by the liver and 
excretion into bile with or without prior biotransformation 
(Klaassen and Rozman, 1991). Therefore, urinary recovery of 
ingested health protective substance could be a reasonable 
indicator for its bioavailability. In addition, health 
protective effects of dietary substances depend on their 
active forms which may be parent compounds and/or their 
metabolites. Establishment of bioavailability and kinetics 
model for those active forms will be crucial. 
Bioavailability data are the "bridges" between dietary 
doses and their health protective effects (end-points). Based 
on the review of data from doses, end-point effects and 
bioavailability, we can assess what will be the optimal dose 
range. If we also know the content of those health protective 
substances in our foods which is another important aspect of 
research, we will be able to determine whether their health 
protective activities can be achieved through human food 
consumption, and to propose better dietary recommendations. 
Plasma and urinary isoflavones in humans and animals 
So far the most detailed characterization of isoflavones 
and lignans in human plasma was reported by Adlercreutz et al. 
in 1993 b. In this study, two fractions (free + sulfate, and 
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glucuronide) of four isoflavones (daidzein, O-
desmethylangolensin, equol and genistein), and three lignans 
(matairesinol, enterodiol and enterolactone) were measured. 
Subjects in the plasma experiment included 28 Finnish women 
(14 omnivores and 14 vegetarians) and six Japanese men who eat 
a traditional Japanese diet. Three day plasma was pooled for 
analysis. Among Finnish women, except for both fractions 
(free + sulfate, and glucuronide) of matairesinol and equol, 
as well as glucuronide fraction of genistein, all the mean 
values of plasma isoflavones and lignans are significantly 
greater in the vegetarians. Among female vegetarian subjects, 
mean values of total daidzein, genistein, equol and O-
desmethylangolensin are 18.5 nmol/L, 17.1 nmol/L, 0.7 nmol/L, 
and 0.8 nmol/L, respectively. For six men who eat a 
traditional Japanese diet, their plasma concentrations of 
total daidzein, genistein, equol and 0-desmethylangolensin 
vary from 60-924 nmol/L, 90-1204 nmol/L, 0.54-24.6 nmol/L, and 
0.98-223 nmol/L, respectively. In both studies, fraction of 
free and sulfate isoflavones count for about 20% of total 
isoflavones. Since phenolic sulfates are easily to be used by 
cells and function as their free forms (Pasqualini et al., 
1989), these provide an important clue for further 
understanding the relationship between isoflavone 
bioavailability and potential health protective effects. 
Adlercreutz et al. (1995) also summarized their data 
regarding urinary excretion of lignans and isoflavones in 
various populations (Finnish women, American women, oriental 
immigrant women on Hawaii, breast cancer patients, and 
Japanese women and men), and dietary groups (omnivores, 
vegetarians, lacto-ovovegetarians, macrobiotics and 
traditional Japanese diet). American macrobiotics, lacto-
ovovegetarians and Japanese men have the greatest amount of 
urinary isoflavone excretions which are 3412-8770 nmol/day, 
885-2188 nmol/day, and 1820-3630 nmol/day, respectively. 
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Japanese women have the greatest variation (347-6610 
nmol/day). Finnish breast cancer patients have the lowest 
urinary isoflavone excretion (67.5-324 nmol/day). However, no 
dietary isoflavone intake data were presented in these 
studies. 
Equol is the bacterial metabolite of daidzein in animals 
and humans (Setchell et al., 1984). P-ethyl phenol is 
proposed to the major metabolite of genistein by gut bacteria 
(Setchell and Adlercreutz, 1988). Equol has attracted 
attention in the past because it was implicated as the main 
cause for permanent and temporary infertility in sheep grazing 
on certain cultivars of subterranean clover which contains 
phytoestrogens (Shutt and Cox, 1972). Ruminant animals showed 
great phase II biotransformation ability outside liver, by 
gastrointestinal epitheliiom. Small intestine homogenate of 
cows has 7 0-100 % greater conjugative activity than that of 
sheep. This difference was used to explain the much lower 
susceptibility of phytoestrogen toxicities in cows which also 
ingest great amounts of isoflavones from subterranean clover 
as sheep do (Lundh, 1990). The implications of this finding 
for human isoflavone metabolism is not known. 
In recent years, bioavailability of soy isoflavones has 
been intensively studied by our laboratory. Tew et al. (1995 
a, b) investigated the effects of dietary fat and fiber 
content upon human soy isoflavone bioavailability. In the 
study of effect of dietary fat, seven healthy women were 
randomly assigned to low or high fat diet (20% or 40% of 
Kcalories from fat, respectively) containing a single dose of 
0.9 mg isoflavones /kg body wt from tofu or texturized 
vegetable protein for one day. Bioavailability as reflected 
on their 24 h urinary isoflavone recoveries was not influenced 
by the amount of diet fat intake. In a similar cross-over 
design experiment, a controlled diet or a wheat fiber 
supplemented diet (contain 15 g and 40 g of dietary fiber, 
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respectively) was assigned to the subjects with the same 
dosage as fat study. Plasma concentration of genistein at 24 
h after dose and 24 h urinary recovery of genistein among 
subjects had wheat fiber supplemented diet were significantly 
less than those in controlled diet. These results suggested 
that majority of isoflavones are less likely absorbed at 
proximal small intestine as aglycones, and gut bacteria may 
involved in the absorption process and play an important role 
after proximal small intestine. 
In addition to human feeding studies, our laboratory has 
also characterized disposition of the same doses (1 mmol/ kg 
diet) of pure isoflavones (daidzein and genistein) or flavone 
(apigenin) with basal diet in rats after four day feeding in 
the metabolic cages, as well as isoflavones and flavone's 
effect on glutathione peroxidase activity in peripheral blood 
lymphocytes and liver cytosol (Lin, 1994). As reflected on 
their urinary recoveries, daidzein had greater bioavailability 
than genistein, and apigenin has lower bioavailability than 
both isoflavones. Both isoflavones reached steady state after 
3 day feeding in rats. Plasma concentrations of daidzein and 
genistein in fourth day were about 1 and 0.8 |1M, respectively. 
Glutathione peroxidase activity in peripheral blood 
lymphocytes and liver cytosol among isoflavones and flavone 
treatments were not significantly different from basal diet 
control. 
In conclusion, higher plasma concentrations and urinary 
excretion of isoflavones were associated with soy food intakes 
in the populations had lower breast, colon and prostate cancer 
risk. In contrast, much lower urinary excretion of 
isoflavones was found in breast cancer patients. Dietary 
fiber but not fat content could affect human bioavailability 
of isoflavones. Furthermore, isoflavones seem to have better 
bioavailability than flavone (apigenin). 
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Analytical methods for isoflavones in urine, plasma and feces 
Isotope dilution gas chromatography-mass spectrometry 
methods for urine and plasma analysis of conjugated and 
unconjugated daidzein, genistein, equol and O-
desmethylangolensin as well as lignans were developed by Dr. 
Adlercreutz's lab (Adlercreutz et al., 1991b and 1993) . This 
method has provided detailed characterization of isoflavones 
and lignans in plasma and urine. 
In this method, conjugated and unconjugated isoflavones 
and lignans in plasma and urine samples were first extracted 
by Sep-Pak C^g reverse-phase column following by ion-exchange 
chromatography on DEAE-Sephadex column (acetate form) to 
clean-up and concentrate analytes. Free diphenols and 
solvolyzed mono- and disulfated diphenols were washed out by 
methanol. Fractions of glucuronides washed out from DEAE-
Sephadex column by 0.3 M lithium chloride and 0.1 M of formic 
acid in 70 % methanol in water (v/v) were hydrolyzed by 
glucuronidase. Both fractions were further purified and 
concentrated on a QAE-Sephadex column (acetate form). 
Estrogens, lignans and equol were first eluted with methanol 
from the column, and then further extracted on carbonate form 
QAE-Sephadex column. Daidzein, genistein and 0-
desmethylangolensin were washed out from acetate form QAE-
Sephadex column with 0.2 M acetic acid in methanol. 
Isoflavones and lignans were separated on a 0.2 mm x 12.5 m 
bonded phase BP-1 (SGE) vitreous silica column with Helium as 
the mobile phase. The temperature of the oven was first kept 
at 100°C for 1 min and then increased by 30°C/min to 280°C. 
The column was directly connected to the ionization chamber. 
After chemical ionization, isoflavones and lignans were 
identified in mass spectrometer by m.onitoring representive ion 
mass and compared with their standards mass spectrum. The 
approximate retention times of the 7 diphenols and the ions 
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monitored were 7.6, 7.9, 8.6, 9.0, 9.5, 9.8 and 11.2 min, 
respectively, for 0-desmethylangolensin, equol, enterodiol, 
enterolactone, daidzein, genistein and matairesinol. 
Radiolabeled isoflavones and lignans were used as internal 
standards to assess loss during the extractions. Recoveries 
varied between 85.6 and 99.0%. The minimum concentrations 
that can be detected varied between 0.2 and 1.0 nmol/L 
depending on the form of isoflavone and lignan by this method. 
High performance liquid chromatography with UV detection 
method which we are currently using for analysis of hydrolyzed 
isoflavones in plasma and urine was modified from the method 
described by Lundh et al. (1988) . Compared with GC-MS method, 
HPLC analysis cost less, require shorter sample preparation 
time, and well serve the purpose for routine analysis of large 
sample quantity. 
In this method, conjugated isoflavones were first 
hydrolyzed by P-glucuronidase and sulfatase to produce their 
aglycones. Isoflavones were extracted by Extrelut column 
following by liquid-liquid solvent extraction in plasma to 
clean-up and concentrate, or Sep-Pak cartridge to achieve 
the same objective. Gradient elution from 40% methanol in 
water (v/v) to 7 0% methanol in water (v/v) can separate 
daidzein, equol and genistein on a C^g reverse-phase column 
within 3 0 min. Recoveries of daidzein, genistein and equol 
were 84-92%, 76-84% and 62-74%, respectively. Detection limit 
of our system is about 0.2-0.4 ,LLM. 
Fecal sample preparation method was modified from soy 
food analysis described by Murphy (1982). Isoflavones were 
then partly purified and concentrated by Sep-Pak Cj^g cartridge 
and analyzed by the same system as urine samples. 
Effort to detect both isoflavone aglycones and conjugates 
at same time by HPLC and photodiode array detector has been 
made by our laboratory. Briefly, 2 ml of urine or plasma 
samples were mixed with 1 ml of 1.5 M sodium acetate buffer 
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(PH=3), then samples were further purified and concentrated on 
Sep-Pak C^g cartridge, and plasma samples were further 
concentrated under Nj gas. HPLC conditions were the same as 
described by Wang and Murphy (1994) . This method works well 
for urine samples although it was difficult to detect 
aglycones from plasma. Using more sensitive detection and/or 
increasing sample size would enhance the sensitivity of this 
method. 
Currently Barnes et al. (1994) has reported a HPLC- mass 
spectrometry method for detection of unconjugated and 
conjugated isoflavones and their major metabolites in human 
serum. The sensitivity was increased about 50-fold by 
capillary reversed-phase HPLC column (0.3 mm i.d.) and 
electrospray ionization compared to the reversed-phase column 
with 2.1 mm i.d.. By this method the smallest isoflavone 
concentrations that can be detected were 1-2 nmol/L. It 
introduces the isoflavone conjugates directly into the mass 
spectrometer without the necessity of hydrolysis or 
derivatization as GC-MS methods. However, further development 
of this method is essential before its broad use in routine 
analysis. 
Compared with GC-MS and HPLC-MS methods, our HPLC-UV 
detection method is less expensive, requires shorter sample 
preparation time and has sufficient sensitivity for routine 
analysis of isoflavones in physiological fluids of feeding 
studies. The GC-MS and HPLC-MS methods described here are 
relatively more sensitive than our method (detection limit is 
about 100 times smaller than that of HPLC-UV method). They 
are capable of detecting and quantifying isoflavone aglycones 
in plasma for epidemiological studies, and can provide more 
detailed characterization of isoflavones and their metabolites 
in plasma and urine. 
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Based on this literature review we know that soybean and 
soybean foods contain substantial amounts of isoflavones. The 
amounts of isoflavone isomers are different among soy foods. 
Isoflavones have broad biological functions and many of them 
could be beneficial in maintaining human health. Modern 
analytical technologies have enabled us to quantify trace 
amount of isoflavones in both soybean foods and physiological 
fluids. From many in vitro and in vivo studies, we can 
hypothesize that isoflavones from soy food consumption may 
perform a health protective effect when they reach certain 
concentrations in the systemic circulation and at target 
tissues. Soybean foods under certain dietary pattern with 
different isoflavone isomers and nutrient content might yield 
different extent of biological functions due to variation of 
isoflavone bioavailability profile. To test our hypothesis we 
conducted a series of human feedings. Our research aims are: 
1) to further characterize the human disposition and 
bioavailability of soy isoflavones under controlled condition; 
2) to evaluate the effect of soy food type and background diet 
upon isoflavone bioavailability; 3) to assess potential health 
protective roles of isoflavones from physiologically 
achievable amounts of soy food consumption. 
Dissertation organization 
The dissertation is composed of four complete papers, 
already published in (I), accepted for publication in (II), or 
to be submitted to (III and IV) professional journals. The 
first paper examines the bioavailability of single dose soy 
milk isoflavones in adult women after a controlled liquid 
diet. The second paper investigates isoflavone 
bioavailability after female subjects ingested three meals of 
soy milk for a day in controlled liquid diet. The third paper 
examines the effect of diet selection and type of soy foods 
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upon the human bioavailability of isoflavones. The fourth 
paper examines the effect of isoflavones bioavailability upon 
blood natural killer cell and glutathione peroxidase 
activities as well as prostaglandin level after seven days soy 
milk feeding in both male and female subjects. Following the 
fourth paper is a general conclusion chapter. 
Literature cited 
Adlercreutz, H., Honjo, H., Higashi, A., Fotsis, T., 
Hamalainen, E., Hasegawa, T., and Okada, H. (1991) 
Urinary excretion of lignans and isoflavonoid 
phytoestrogens in Japanese men and women consuming a 
traditional Japanese diet. Am. J. Clin. Nutr. 54: 1093-
1100 . 
Adlercreutz, H., Fotsis, T., Bannwart, C., Wahala, K., Brunow, 
G. and Hase T. (1991b) Isotope dilution gas 
chromatographic-mass spectrometric method for the 
determination of lignans and isoflavonoids in human urine, 
inclusing identification of genistein. Clinica Chimica 
Acta. 199: 263-278. 
Adlercreutz, H., Mousavi, Y. , Clark, J., Hockersted, K., 
Hamalainen, Wahala, K., Makela, T. and Hase, T. (1992) 
Dietary phytoestrogens and cancer: in vitro and in vivo 
studies. J. Steroid Biochem. Molec. Biol. 41: 331-337. 
Adlercreutz, H., Bannwart, C., Wahala, K., Makela, T. , Brunow, 
G., Hase, T., Arosemena, P.J., Kellis, J.T. and Vickery, 
L.E. (1993a) Inhibition of human aromatase by mammalian 
lignans and isoflavonoid phytoestrogens. J. Steroid 
Biochem. Molec. Biol. 44: 147-153. 
Adlercreutz, H., Fotsis, T., Lampe, J., Wahala K, Makela, T., 
Brunow, G. and Hase, T. (1993 b) Quantitative 
determination of lignans and isoflavonoids in plasma of 
omnivorous and vegetarian women by isotope dilution gas 
chromatography-mass spectrometry. Scand. J. Clin. Lab 
Invest. 53(suppl 215): 5-18. 
Adlercreutz, H., Goldin, B.R., Gorbach, S.L., Hockerstedt, 
K.A.V., Watanabe, S., Hamalainen, E.K., Markkanen, M.H., 
Makela, T.H., Wahala, K.T., Hase, T. and Fotsis, T. (1995) 
Soybean phytoestrogen intake and cancer risk. J. Nutri. 
125: 757S-770S. 
20 
Akiyama, T., Ishida, J., Nakagawa, S., Ogaware, H., Watanable, 
S., Itoh, N., Shibuya, M. and Fukami, Y. (1987) Genistein, 
a specific inhibitor of tyrosine-specific protein kinases. 
J. Biol. Chem. 262: 5592-5595. 
Barnes, S., Grubbs, C., Setchell, K.D., and Carlson, J. 
(1990) Soybeans inhibit mammary tumors in models of 
breast cancer. Clin. Biol. Res. 347: 239-253. 
Barnes, S., Kirk, M. and Coward, L. (1994) Isoflavones and 
their conjugates in soy foods: extraction conditions and 
analysis by HPLC-Mass Spectrometry. J. Agric. Food Chem. 
42: 2466-2474. 
Baxevanis, C.N., Reclos, G.J., Gritzapis, A.D., Dedousis, 
V.Z., Missitzis, I. and Papamichail, M. (1993) Elevated 
prostaglandin E2 production by monocytes iis responsible 
for the depressed levels of natural killer and lymphokine-
activated killer cell function in patients with breast 
cancer. Cancer. 72: 491-501. 
Bickoff, E.M., and Livingston, A.L., Hendrickson, A.P. and 
Booth, A.N. (1962) Relative potencies of several estrogen­
like compounds found in forages. J. Agric. Food Chem. 10: 
410-412 . 
Borrego, F., Pena, J. and Solana, R. (1993) Regulation of CD69 
expression on human natural killer cells: differential 
involvement of protein kinase C and protein tyrosine 
kinases. Eur. J. Immunol. 23: 1039-1043. 
Campbell, D.R. and Kurzer, M.S. (1993) Flavonoid inhibition of 
armatase enzyme activity in human preadipocytes. J. 
Steroid Biochem Molec. Biol. 46: 381-388. 
Clark, J.H., Schrader, W.T. and O'Malley, B.W. (1985) 
Mechanisms of steroid hormone action. In: Textbook of 
Endocrinoloby, Seventh Edition (Wilson, J.D. and Foster, 
D.W., eds), pp.33-75. W.B. Saunders Company, Philadelphia, 
PA. 
Farmakalidis, E., Hathcock, J.N. and Murphy, P.A. (1985) 
Oestrogenic potency of genistin and dadzin in mice. Food 
Chem. Toxicol. 23: 741-745. 
Finlay, G.J., Smith, G.P., Frey, L.M. (1988) Effect of flavone 
acetic acid on Lewis lung carcinoma: evidence for an 
indirect effect. J. Natl. Cancer Inst. 80: 241-245. 
21 
Fitzsiminons, J.T.R., Orson, N.V. and El-Aaaser, A.A. (1989) 
Effects of soybean and ascorbic acid on experimental 
carcinogenesis. Comp. Biochem. Physiol. 93A: 285-290. 
Fotsis, T., Pepper, M. , Adlercreutz, H., Flerischmann, G., 
Hase, T., Montesano, R. and Schweigerer, L. (1993) 
Genistein, a dietary-derived inhibitor of in vitro 
angiogenesis. Proc. Natl. Acad. Sci. USA. 90: 2690-2694. 
Hendrich, S., Lee, K.W., Xu, X., Wang, H.J., and Murphy, 
P.A. (1994) Defining food components as new nutrients. 
J. Nutr. 124: 1789S-1792S. 
Higashi, K. and Ogawara, H. (1992) Effects of isoflavone 
compounds on the activation of phospholipase C. Chem. 
Pharm. Bull. 40: 157-160. 
Ho, C-T. (1992) Phenolic compounds in food. In: Phenolic 
compounds in food and their effects on health I (Ho, C-
T., Lee, C.Y. and Huang, M-T. eds), pp.2-7. American 
Chemical Society, Washington, DC. 
Huang, M-T. and Ferraro, T. (1992) Phenolic, compounds in food 
and cancer prevention. In: Phenolic compounds in food and 
their effects on health II (Huang, M-T, Ho, C-T. and Lee, 
C.Y., eds), pp. 8-34. American Chemical Society, 
Washington, DC. 
Klaassen, C.D. and Rozman, K. (1991) Absorption, distribution, 
and excretion of toxicants. In: Casarett and Doull's 
Toxicology - the Basic Science of Posions, 4th Edition ( 
Amdur, M.O., Doull, J. and Klaassen C.D., eds), pp. 50-87. 
Pergamon Press, Elmsford, NY. 
Kudou, S., Fleury, Y., Welti, D., Magnolato, D., Uchida, T., 
Kitamura, K. and Okubo, K. (1991) Malonyl isoflavone 
glycosides in soybean seeds (Glycine max MERRILL). Agric. 
Biol. Chem. 55: 2227-2233. 
Kuhnan, J. (197 6) The flavonoids. A class of semi-essential 
food components: their role in human nutrition. World Rev. 
Nutr. Diet. 24: 117-191. 
Lee, K.W., Wang, H-J, Murphy, P.A. and Hendrich, S. (1995) 
Soybean isoflavone extract suppresses early but not later 
promotion of hepatocarcinogenesis by phenobarbital in 
female rats. Nutri. and Cancer (submitted). 
22 
Lin, H.K. (1994) Genistein, daidzein and apigenin 
bioavailability and effects on glutathione peroxidase 
activity. Master thesis, Iowa State University, Ames, 
Iowa. 
Lundh, T.J.O. (1990) Conjugation of the plant estrogens 
formononentin and daidzein and their metabolite equol by 
gastrointestinal epitheliiim from cattle and sheep. J. 
Agric. Food Chem. 38: 1012-1016. 
Lundh, T.J.O., Pettersson, H., and Kiessling, K.H. (1988) 
Liquid chromatographic determination of the estrogens 
daidzein, formononetin, coumestrol, and equol in bovine 
blood plasma and urine. J. Assoc. Off. Anal. Chem. 71: 
938-941. 
Marshall, P., Kulmacz, R.J. and Lands, W.E.M. (1988) 
Constraints on prostaglandin biosynthesis in tissues. J. 
Biol. Chem. 262(8): 3510-3517. 
Messina, M. and Barnes, S. (1991) The role of soy products in 
reducing risk of cancer. J. Natl. Cancer Inst. 83: 541-
546 . 
Molteni, A., Brizio-Molteni, L. and Persky, V. (1995) In vitro 
hormonal effects of soybean isoflavones. J. Nutri. 125: 
751S-756S. 
Murphy, P.A. (1982) Phytoestrogen content of processed soybean 
products. Food Technol. 36: 62-64. 
Nairn, M., Gestetner, B., Bondi, A., and Birk, Y. (1975) 
Antioxidative and antihemolytic activity of soybean 
isoflavones. J. Agric. Food Chem. 24: 1174-1177. 
Pasqualini, J.R., Gelly, C., Nguyen, B.L. and Vella, C. (1989) 
Importance of estrogen sulfates in breast cancer. J. 
Steroid Biochem. 34: 155-163. 
Peterson, G. and Barnes, S. (1991) Genistein inhibition of 
the growth of human breast cancer cells: independence 
from estrogen receptors and the multi-drug resistence 
gene. Biochem. Biophys. Res. Commu. 179: 661-667. 
Pratt, D.E., and Birac, P.M. (1979) Source of antioxidant 
activity of soybeans and soy products. J. Fd. Sci. 
44: 1720-1722. 
23 
Setchell, K.D.R., Borriello, S.P., Hulme, P., Kirk, D.N., 
and Axelson, M. (1984) Nonsteroidal estrogens of dietary 
origin: possible roles in hormone-dependent disease. Am. 
J. Clin. Nutr. 40: 569-578. 
Setchell, D.K.R. and Adlercreutz, H. (1988) Mammalian ligans 
and phytoestrogens. Recent studies on their formation, 
metabolism and biological role in health and disease. In: 
Role of the Gut Flora in Toxicity and Cancer (Rowland, 
I.R., ed.), pp.315-345. Academic Press, London, U.K. 
Shutt, D.A. and Cox, R.I. (1972) Steroid and phytoestrogen 
binding to sheep uterine receptors in vitro. I. 
Endocrinol. 52: 299-310. 
Tew,- B-Y., Wang, H-J., Murphy, P.A. and Hendrich S. (1995a) 
Dieatry fat content and isoflavone bioavailability in a 
single meal fed to women. J. Nutri. (submitted). 
Tew, B-Y, Xu, X., Wang, H-J., Murphy, P.A. and Hendrich, S. 
(1995b) A diet high in wheat fiber decreases the 
bioavailability of soybean isoflavones in a single meal 
fed to women. J. Nutri. (in press). 
Traganos, F., Ardelt, B., Halko, N., Bruno, S. and 
Darzynkiewicz, Z. (1992) Effects of genistein on the 
growth and cell cycle progression of normal human 
lymphocytes and human leukemic MOLT-4 and HL-60 cells. 
Cancer Research. 52: 6200-6208. 
Verdeal, K., Brown, R.R., Richardson, T. and Ryan, D.S. (1980) 
Affinity of phytoestrogen for estradiol-binding proteins 
and effect of coumestrol on growth of 7, 12-
dimethylbenz(a) anthracene-induced rat mammary tumors. J. 
Natl. Cancer Inst. 64: 285-290. 
Wang, H.J., and Murphy, P.A. (1994) Isoflavone content in 
commercial soybean foods. J. Agric. Food Chem. 42: 
1666-1673. 
Wei, H., Bowen, R., Cai, Q., Barnes, S. and Wang, Y. (1995) 
Antioxidant and antipromotional effects of the soybean 
isoflavone genistein. Processings of the Society for 
Experimental Biology and Medicine. 208(1): 124-130. 
Willett, W.C. (1994) Diet and health: what should we eat? 
Science. 264: 532-537. 
24 
Whiteside, T.L. and Herberman, R.B. (1989) The role of natural 
killer cells in hiunan disease. Clinical Iitunun. Iiranunopath. 
53: 1-23. 
Wiltrout, R.H. and Hornung, R.L. (1989) Natural products 
antitumor agents: direct versus indirect mechanisms of 
activity of flavonoids. J. of the National Cancer 
Institute 80: 220-222. 
Isoflavones: 
25 
R1= H, R2= H, Daidzein 
R1= OH, R2= H, Genistein 
R1= H, R2= 0CH3, Glycitein 
R1 O 
Flavones: 
R1= H, R2= H, Apigenin 




R1= H, R2= H, Naringenin 
R1=0H, R2=0H, Taxifolin 
Figure 1: Types and structures of common flavonoids 
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I. DAIDZEIN IS A MORE BIOAVAILABLE SOYMILK ISOFLAVONE THAN 
IS GENISTEIN IN ADULT WOMEN^'^ 
A paper published in the Journal of Nutrition 
Xia Xu, Huei-Ju Wang, Patricia A. Murphy, Laura Cook and 
Suzanne Hendrich^ 
Abstract 
Soybean isoflavones are proposed to be 
anticarcinogenic. In order to study their disposition in human 
body, twelve young adult human females were fed single doses 
of 0.7, 1.3 and 2.0 mg isoflavones/kg body weight in soybean 
milk as part of a liquid diet. Plasma, urine and fecal 
isoflavones were measured by reverse phase HPLC. Average 24 h 
urinary recovery of daidzein and genistein was about 21% and 
9% respectively at all three doses. Urinary recovery of 
daidzein was significantly greater than that of genistein 
(p<0.001). Total fecal excretion of isoflavones was only 1-2% 
of the ingested amount. Plasma total isoflavone concentration 
was significantly increased to 4.4±2.5 |iinol/L at 6.5 hours 
after a dose of 2.0 mg/kg. The plasma concentrations of 
daidzein and genistein were approximately equal. Twenty-four 
hours after dosing, both plasma and urine isoflavone 
concentrations were nearly nil. Although soybean milk 
isoflavones seem to be 85% degraded in the intestine, the 
systemic bioavailability, especially of daidzein, may be 
sufficient to exert some health-protective effects. 
^Supported by NIH grant CA-56308-02, Journal paper No. J-
15502,Iowa Agriculture and Home Economics Experiment Station, 
Project No. 3075. 
^Reprinted with permission from J. of Nutri. 1994, 124: 825-
832. Copyright © 1994 J. of Nutri. 
^Author for correspondence 
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Introduction 
Genistin, daidzin and their aglycones, genistein and 
daidzein are the major isoflavones in soybean foods (Murphy 
1981 and 1982) . In addition to their estrogenic activity, ten 
to one-thousandfold less than estradiol in the mouse uterine 
growth assay (Bickoff et al. 1962, Farmakalidis et al. 1985), 
and their antiestrogenic activity (Adlercreutz et al. 1986, 
Setchell and Adlercreutz 1988), they also possess antifungal 
(Naim et al. 1974), antiviral (MacRae et al. 1989, Markkanen 
et al. 1981,) and antioxidant activities (Naim et al. 1976) . 
Antiestrogenic and antioxidant activities are proposed to be 
anticarcinogenic (Adlercreutz et al. 1987, Adlercreutz 1988, 
Fisher et al.l988). Genistein also inhibits tyrosine kinases 
(Akiyama et al. 1987), and blocks angiogenesis in vitro 
(Fotsis et al. 1993) which are also proposed mechanisms of 
anticarcinogenesis. Because of their biological effects and 
their abundance in soybean foods (0.1-1.5 mg/g, Wang and 
Murphy 1993), the isoflavones may be of great potential 
benefit to human health maintenance. 
The incidence of and mortality from breast cancer in the 
Western world are much higher than in Asia where soybeans are 
an important part of the diet (Armstrong and Doll 197 5, Dunn 
1975, Rose et al. 1986). Dietary factors are suggested as a 
cause of the increasing breast cancer rate among successive 
generations of Japanese in California as compared with the 
rate in Japan (Dunn 1975). Japanese women and women of 
Japanese origin in Hawaii consuming a diet similar to the 
traditional Japanese diet have low breast cancer incidence and 
mortality (Nomura et al. 1978, Smith 1956). Breast cancer 
patients excrete about 21% less of the isoflavone metabolite, 
equol, when compared with either vegetarian or omnivorous 
controls (Adlercreutz et al. 1982). Urinary isoflavone 
excretion was 20-30 times greater among Japanese women and men 
consuming a typical traditional diet compared with the values 
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obtained from women living in Boston and Helsinki. Soybean 
product consumption was the source of urinary isoflavones in 
Japan (Adlercreutz et al. 1991a). 
Feeding a 3 0% soybean diet protects mouse liver from 
nitrosamine-induced cancer (Fitzsimmons et al. 1989), although 
this protective effect was not specifically attributable to 
isoflavones. Rats consuming a soybean-based diet develop fewer 
mammary tumors following administration of the carcinogens N-
methylnitrosourea and 7,12-dimethylbenz[a]-anthracene than 
rats on isonitrogenous and isocaloric diets without soybeans 
(Barnes et al. 1990). The anticarcinogenic effect of soy was 
probably due to isoflavones. Genistein inhibits the growth of 
estrogen receptor-negative or -positive human breast cancer 
cell lines (concentration for inhibition of 50% cell growth, 
IC5O=24 .1-44 .4 |iinol/L; Peterson and Barnes 1991). Genistein 
also inhibits tyrosine kinases, a major class of oncogene 
products regulating tumor cell growth, and DNA topoisomerase 
II, an enzyme needed for DNA replication (Traganos et al. 
1992) . 
These findings suggest that a Western diet may lack 
certain cancer-protective factors which are present in 
soybeans. The antiestrogenic and antioxidant isoflavones, 
genistin and daidzin may be the most significant of these 
factors. The isoflavone aglycones, daidzein, genistein and 
metabolites, have been detected and identified in human 
biological fluids, especially in urine (Adlercreutz et al. 
1982 and 1991b, Axelson et al. 1982, Bannwart et al. 1984a and 
1984b). Urinary excretion of the isoflavone metabolites, 
equol and 0-desmethylangolensin, was compared among women 
consuming omnivorous, lactovegetarian, or vegetarian diets. 
The largest amounts of equol and 0-desmethylangolensin were 
found in the urine of the vegetarian group (Adlercreutz et al. 
1986) . 
Urinary isoflavones and their metabolites were measured 
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in a group of Japanese women and men who consumed a typical 
traditional diet (Adlercreutz et al. 1991a), Three-day food 
intake records were made to estimate their food consumption. 
Very high levels of urinary daidzein, equol and 0-
desmethylangolensin were found, although the interindividual 
variation was great. Urinary isoflavone excretion correlated 
closely with soybean and soybean product intake (r=0.75, 
p<0,001) , 
Previous studies of human isoflavone metabolism have not 
fed carefully controlled diets. No human isoflavone 
dose/response studies have been performed. When urinary 
isoflavones were compared among different dietary groups, the 
amount of isoflavones ingested was not measured. Because of 
the possible anticarcinogenicity of isoflavones, human 
absorption and excretion of soyfood isoflavones is of 
interest. This information will be useful in determining the 
anticarcinogenic potency of isoflavones, using a variety of 
endpoints. 
In this study, a group of young female adults were fed 
three single doses of isoflavones from soymilk in a well 
controlled liquid diet. Plasma, urine and fecal isoflavone 
content were measured after feeding. 
Subjects and methods 
The subjects were twelve young adult females between 19 
and 33 years of age, with body weight of 63.2±9.4 kg and body 
mass index of 22.5±2.2 kg/m^ (Table 1). 
All the subjects were in good health, based on medical 
histories and physical examinations performed by Student 
Health Center physicians at Iowa State University (ISU). The 
procedures for this feeding study were approved by the Human 
Subjects Committee of ISU, with prior approval of the U.S. 
Food and Drug Administration. All the subjects were omnivorous 
and most had never eaten soybean foods before the feeding 
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started. 
The study consisted of three feeding days, each separated 
by a two-week washout period (Table 1). On each feeding day, 
subjects were fed three nutritionally complete liquid meals. 
Breakfast contained soy milk powder reconstituted with 
distilled water (Now Foods, Inc., Glendale Hts., IL) mixed 
with chocolate-flavored Carnation Instant Breakfast® (Nestle 
Food Company, Glendale, CA) diluted with whole milk. Lunch and 
dinner consisted of chocolate-flavored Carnation Instant 
Breakfast® reconstituted with whole milk. Subjects' energy 
requirements were estimated based on their age, body weight, 
and physical activity levels according to the Recommended 
Dietary Allowances tables (Food and Nutrition Board, National 
Research Council, 1989). Subjects were asked not to consume 
anything for 10 h before dosing. Lunch and dinner were fed at 
five hour intervals after dosing. Subjects were instructed not 
to eat anything other than what was given on the feeding day. 
They were also asked not to eat any foods containing 
texturized vegetable protein, hydrolyzed vegetable protein, 
and soy protein isolate during the washout periods. No adverse 
effects such as diarrhea were reported after soybean food 
dosing. 
Biological Sample Collection 
Blood samples. Five mL venous blood samples were collected in 
heparinized vacutainers by medical technologists under stringent 
aseptic conditions at the Student Health Center, ISU. A blood 
sample was collected within 1 h before dosing (Time "0"). Blood 
samples were also collected at 6.5 and 24 h after dosing. 
Samples were centrifuged within one hour after collection at 
3 000 X g for 20 minutes at 4°C (Model 4D; International 
Equipment Co., Needham Hts., MA), and plasma was stored in a -
20°C freezer. 
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Urine samples. For each subject, a urine sample was collected 
in the morning before dosing (Time "0"). All urine was 
collected and pooled in two 12 h increments during the first 
24 h after dosing. The first urination of the second day after 
dosing was also collected. After recording the total volume, 
50 mL of each of the four samples was stored in a -20°C 
freezer. 
Fecal samples. Capsules containing 1 g carmine red 
(Pharmaceutical Service, University of Iowa, Iowa City, lA) 
were given with the soymilk. One fecal sample from each 
subject was collected before soymilk feeding (Time "0"). After 
dosing, all feces excreted before and during fecal marker 
excretion were collected. Usually, the fecal marker appeared 
in feces one or two days after dosing. Fecal sample 
collection was stopped when fecal marker no longer appeared in 
feces. After collecting the fecal samples, feces were freeze 
dried. After recording all the weights of dry samples, feces 
were ground to a fine powder in a coffee mill (Braun Company 
Inc., Lynnfield, MA). Ten g of each dry fecal sample was 
stored in a -20°C freezer until analysis. 
Soybean Milk Powder Analysis 
Two g samples in triplicate of both soymilk powder and 
chocolate-flavored Carnation Instant Breakfast® were used for 
analysis. Total isoflavones were measured as free isoflavones 
after hydrolysis in 1 mol/L HCl. Sample preparation followed 
the method described by Wang et al. (1990). Reverse phase HPLC 
analysis was performed in a 4.6 mm i.d. x 25 cm length, 5 |J. Cis 
ultrasphere column (Beckman Instruments, Inc., Berkeley, CA) . 
Gradient elution as described by Murphy (1981) was achieved by 
two pumps, ALTEX model llOA (ALTEX Scientific, Inc. Berkeley, 
CA) and Beckman model llOA, controlled by a ALTEX model 420 
microprocessor solvent flow controller. Hydrolyzed daidzein 
and genistein in soymilk powder were identified and quantified 
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by a Waters 991 photodiode array detector connected with a NEC 
computer system (Millipore Corporation, Milford, MA). 
Biological Sample Analysis 
After metabolism, in human plasma and urine about 90% of 
isoflavones and their major metabolites are present as 
glucuronides, and about 3-5% as sulfates (Adlercreutz et al. 
1991b, Axelson et al. 1982 and 1984, Setchell et al. 1984) . 
Plasma and urine samples were treated with glucuronidase/ 
sulfatase (Sigma Chemicals Company, St. Louis, MO) to produce 
the parent isoflavones (Lundh et al. 1988). 
Plasma and urine samples. Sample preparation for plasma and 
urine isoflavone analysis was performed according to the 
methods described by Lundh et al. (1988). One mL of plasma and 
2.5 mL of urine were prepared for analysis. Plasma samples 
were dissolved in 150 |IL and urine samples in 2 mL of 80% 
methanol in H2O. A 200 |IL insert into a 2 mL vial (National 
Scientific Company, Lawrenceville, GA) was used for 
autosampling of plasma. Samples were automatically injected 
with a Beckman Model 502 Autosampler. Isoflavones were 
separated in a Waters 3.9 mm i.d. x 3 0 cm length |J,-Bondapak C18 
reverse phase column with gradient elution at ambient 
temperature. Solvent flow controller and pumps were the same 
as used for soymilk powder analysis. The mobile phase included 
methanol, HPLC grade (Fisher brand) and ultrapure Nalgene 
water (Nalge Company, Rochester, NY). A linear gradient was 
run from 40% to 7 0% methanol in 3 0 min at a flow rate of 1 
mL/min. Waters 991 Photodiode Array Detector was used to 
quantitate spectral data from 210 nm-400 nm for each peak. In 
this reverse phase HPLC system, daidzein, equol and genistein 
eluted at 18.4, 20.8 and 23.4 min respectively. Daidzein has a 
maximum absorption at 254 nm, genistein at 263 nm and equol at 
280 nm. 
Daidzein (4',7-dihydroxyisoflavone) was obtained from 
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Life Science Group, ICN Pharmaceuticals, Inc., Plainview, NY. 
Genistein (4',5,7-trihydroxyisoflavone) was obtained from 
Calbiochem Corporation, La Jolla, CA. Equol (4',7-
dihydroxyisoflavondiol) was a generous gift from Dr. H. 
Adlercreutz (Department of Clinical Chemistry, University of 
Helsinki, Finland). 
A series of standards of 1, 2, 4, 8, 12, 16, 24 |imol/L, 
were assayed to quantify isoflavones. For each subject, plasma 
and urine samples were spiked randomly with daidzein, 
genistein and equol standards (0.15 fig isoflavone/100 |U.L added 
to each sample) to measure recovery. 
Fecal samples. Two g ground, freeze-dried fecal samples were 
extracted with 10 mL acetonitrile mixed with 2 mL 0.1 mol/L 
HCl, and then filtered through No.l Whatman filter paper. 
Samples were collected in 20 mL vials and dried under N2. The 
residues were dissolved in 10 mL 20% ethanol/distilled, 
deionized water. The samples were acidified with 200 |iL 1 
mol/L HCl. Five mL of extract was slowly injected onto an 
activated Waters Sep-Pak Cis cartridge. Cartridges were washed 
with 2 mL ultrapure deionized water followed by 2 mL 20% 
methanol/water. The cartridge was washed with 2 mL 80% 
methanol to elute the isoflavones. 
Reverse phase HPLC analysis was performed with two 
Beckman Model llOB pumps,and one Beckman Model 420 
Microprocessor solvent flow controller to produce a gradient 
of 40% to 65% methanol over 30 minutes at flow rate 1 
mL/minute. The same column was used as for plasma and urine 
analysis. Spectra-Physics Autosampler Model 8780XR (Spectra-
Physics, Fremont, CA) was used to inject samples. Variable 
wavelength detector Beckman Model 163 was connected with 
Beckman Model 427 Integrator by which chromatographic data 
were calculated and plotted. 
To ensure the quality of analysis, a series of standards 
(1, 2, 4, 8, 12, 16, 24 |Jinol/L) and fecal samples spiked with 
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500 flL of 32 |jjnol/L daidzein, genistein and equol standards 
were run to measure recovery. 
Statistical Methods 
The statistical analysis was performed with the 
Statistical Analysis System (SAS Institute, Inc., Gary, NC) 
version 6.06 on the Iowa State University mainframe computer. 
Data were tested for heterogeneity of variance. If necessary, 
data were transformed to homogeneity before ANOVA (Snedecor 
and Cochran 1967) . Analysis of variance (GLM) was performed on 
the data obtained from this crossover design experiment. 
Subjects and feeding times were treated as blocks. The effects 
of dosages, measuring times, and kinds of isoflavone upon 
plasma concentration and urinary excretion were determined. If 
the effect from any one of these factors was significant, 
Tukey's test was used for comparison within the factor. A p 
value of 0.05 or less was considered to be significant. 
Results 
Soymilk powder contained 1.25±0.08 mg/g total 
isoflavones; 44% genistein and 56% daidzein. No isoflavones 
were detected in chocolate-flavored Carnation Instant 
Breakfast®. 
At all three doses of isoflavones, 15-20% of the ingested 
total dose was excreted (Table 2). Average 24 h urinary 
recovery of daidzein and genistein was about 21% and 9% 
respectively at each dose. Urinary recovery of daidzein was 
significantly greater than that of genistein (p<0.001). Total 
fecal excretion of isoflavones was 1-2% of the ingested 
amount. No equol was found in any sample although the recovery 
of equol was between 62-74% in all spiked samples. The average 
amount of total urinary isoflavones increased significantly 
with increasing dose (p<0.001). 
Variation in isoflavone content of biological samples was 
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great among the subjects (p<0.05), especially for fecal 
samples. Subject Eight excreted ten times more fecal 
isoflavones than the other subjects at all three dosages. 
At all three doses, the amount of urinary isoflavones was 
about two times greater in the first 12 h after dosing than in 
the second 12 h after dosing (p<0.001)(Table 3). After 24 h, 
urinary excretion of isoflavones was nearly nil. The amount 
excreted in the first twelve hours increased significantly 
with the increase in dosage (p<0.001). There was a strong 
relationship between dose and amount excreted (r=0.88, 
p<0.001). At all three doses of isoflavones, the amount of 
urinary daidzein was significantly greater than that of 
genistein during the first 24 h after dosing (p<0.001). 
Plasma isoflavone concentration was significantly 
increased at 6.5 h after dosing (Table 4). The plasma 
concentrations of daidzein and genistein were not 
significantly different at this time. Twenty-four hours after 
dosing, plasma isoflavone concentration was nearly nil. At 6.5 
h after dosing, a strong correlation was found between plasma 
isoflavone concentration and ingested doses {r=0.87, p<0.001). 
Discussion 
In this study, only 1-2% of ingested isoflavones were 
excreted intact in feces (Table 2). Average 24 h urinary 
recovery of daidzein and genistein was about 21% and 9% 
respectively (Table 2). Because daidzein and genistein in both 
plasma and urine were nearly nil 24 h after dosing, the 
bioavailability of daidzein and genistein at all three doses 
seemed to be about 21% and 9% respectively. 
The urinary recovery of isoflavones depends upon 
absorption from the gastrointestinal tract (Klaassen and 
Rozman 1991, Welling 1986). Human absorption of isoflavones 
after oral administration may be moderate. In healthy male 
volunteers, 40-50% of an ingested single dose of 200 mg 
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ipriflavone was absorbed (Shino 1985) . (Ipriflavone is a 
synthetic isoflavone recently introduced as antiosteoporotic 
agent because of its estrogenic activity.) In dogs, only 
about 24% of 20 mg '•"'C-ipriflavone/kg body weight oral dose was 
considered to be absorbed (Yoshida et al. 1985). The urinary 
recovery is also affected by the first-pass effect: the 
phenomenon of removal of xenobiotics before entrance to the 
systemic circulation. This may be due to biotranformation by 
the gastrointestinal mucosa, extraction by the liver and 
excretion into bile with or without hepatic biotransformation 
(Klaassen and Rozman 1991, Welling 1986). Any substance 
extensively metabolized and excreted in bile is unlikely to 
exhibit good systemic availability regardless of the extent of 
absorption (Welling 1986). Finally, the urinary recovery of 
isoflavones is also influenced by retention of the compounds 
within tissues. Because isoflavones are extensively 
transformed by phase II enzymes (Adlercreutz et al. 1991b, 
Axelson et al. 1982 and 1984, Lundh et al. 1988, Setchell et 
al. 1984), their retention in the human body becomes very 
unlikely. 
Significant retention of isoflavones in the human body is 
improbable. After rats and dogs were orally dosed with 20mg 
^''C-ipriflavone/kg body weight, it was eliminated mostly as 
metabolites within 48 and 72 h respectively. Rats excreted 
more ^''C-ipriflavone and its metabolites in urine than in 
feces, whereas the opposite was observed in dogs (Yoshida et 
al. 1985) . Seemingly, animal species affects the route of 
excretion. In human studies, when a single 2 00 mg dose was 
administered orally to healthy volunteers, ipriflavone was 
rapidly absorbed (Tmax=l. 8 + 0 . 4 h) and extensively metabolized. 
In plasma, only small quantities of the parent compound were 
detected, together with seven metabolites (Shino 1985) . A 
multiple-dose study in healthy volunteers (200 mg x 3/day) 
showed no accumulation of ipriflavone (Suda 1987) . Hydroxyl 
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groups of isoflavones provide sites for phase II 
biotransformation by UDP-glucuronosyltransferases and 
sulfotransferases. Sulfation has a low capacity for 
conjugation of phenols, whereas glucuronidation has a much 
higher capacity. Therefore, when large doses of phenolic 
compounds are given, glucuronidation is the major pathway of 
biotransformation (Sipes and Gandolfi 1991). When rats were 
orally dosed with 50 mg/kg (0.3 mmol/kg) of "C-2-
hydroxybiphenyl, almost 90% of the dose was recovered in urine 
within 24 h and about 75% of the dose was excreted as the 
glucuronides or sulfate esters of the hydroxybiphenyl and its 
metabolites (Reitz et al. 1983). As doses were increased from 
5 mg/kg to 500 mg/kg, the proportion of glucuronides in urine 
was increased by 50%. Human phenol UDP-glucuronosyltransferase 
shows 7 6% amino acid sequence homology with phenol UDP-
glucuronosyltransf erases isolated from rat liver and kidney 
(Harding et al. 1988). Therefore, our study suggests that 
human subjects have a sufficient capacity to perform 
glucuronidation of isoflavones and their metabolites, because 
the subjects were given less than 0.01 mmol total 
isoflavones/kg body weight. 
Although sulfate conjugates of xenobiotics are excreted 
mainly in urine, glucuronides can be excreted from the body in 
either the bile or urine, depending on the molecular weight of 
the aglycone. In the rat, the glucuronide will be cleared by 
renal tubular organic acid secretion into urine, if the 
aglycone has a molecular weight below about 250 (Sipes and 
Gandolfi 1991). If the aglycone has a molecular weight greater 
than 3 50, the conjugate is often secreted into bile. From 
molecular weights of 250-350 the conjugate may be excreted by 
either pathway (Sipes and Gandolfi 1991). Daidzein and 
genistein have molecular weights of 254 and 270 respectively. 
Isoflavones undergo urinary as well as biliary excretion in 
rats (Axelson and Setchell 1981), dogs (Yoshida et al. 1985) 
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and humans (Rondelli et al. 1991). These studies suggest that 
in humans the molecular weights of isoflavones are very likely 
within the range which enables their conjugates to undergo 
partitioning between bile and urine. This is also true of 
estradiol excretion (molecular weight, 272). After liver 
biotransformation about 50% of estradiol conjugates are 
excreted in bile (Gorbach 1984). Isoflavones differ from 
estradiol in humans in that about 85% of estradiol conjugate 
in bile is hydrolyzed by deconjugating enzymes (i.e. (3-
glucuronidases and arylsulfatases) produced by the 
gastrointestinal microbes to form the free hormone which is 
then reabsorbed in the intestinal tract, whereas isoflavones 
are extensively metabolized and degraded by intestinal 
bacteria (Adlercreutz et al. 1986 and 1991, Axelson et al. 
1984, Setchell and Adlercreutz 1988, Setchell et al. 1984). 
The molecular weight cutoffs in humans may be different 
from rats. But, the lesser molecular weight and greater 
water-solubility of daidzein might partly explain its greater 
presence in urine than genistein. The greater molecular weight 
and less water-solubility of genistein may promote excretion 
of its conjugate in bile. But, bacterial degradation of 
isoflavones seemingly occurs to a great extent at the same 
time. This may be why little genistein is recovered in urine 
and feces. 
The bacteria in the gastrointestinal tract play an 
important role in metabolism of isoflavones in humans and 
animals. The condition of the intestinal microflora affects 
the amount and pattern of isoflavone excretion which was also 
extensively changed by antibiotics treatment (Adlercreutz 
1991). The major metabolite of isoflavones, equol, is formed 
by bacteria in humans (Setchell et al. 1984) and animals 
(Batterham et al. 1955, Dickinson et al. 1988, Nilsson et al. 
1967). Besides forming equol, bacteria also produce O-
desmethylangolensin from daidzein (Adlercreutz et al. 1985, 
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Bannwart et al. 1984b) in humans, and produce p-ethylphenol 
from genistein in sheep (Batterham et al. 1965). Intestinal 
bacteria modified 70% of the 9 g/day isoflavones ingested by 
sheep (Shutt et al. 1970). Unlike normal rats, germfree rats 
do not excrete equol when given a soy-containing food (Axelson 
and Setchell 1981). In this study, no equol was found in any 
biological samples. Human gastrointestinal flora can form 
equol from soybean isoflavones both in vivo and in vitro 
(Setchell et al. 1984). One male and one young adult female 
were fed 40 g of commercial textured soybean as a meat 
substitute in lunch for five days. More than 0.1 mg of urinary 
equol was produced per gram of soybean (Axelson et al. 1984) . 
About 1 mg equol/day appeared in urine 24 h after ingesting 
the textured soy and reached a maximum of 4-5 mg/day after 
three days, but only three out of six subjects were equol 
producers (Setchell et al. 1984). This may explain why no 
equol could be found in urine of subjects who ingested only a 
single dose of soymilk. 
Isoflavones may be degraded as well as metabolized in the 
intestine. The C-ring of flavonoids can be cleavaged by human 
intestinal bacteria and 5 mg of quercetin, one of the 
flavonoids, can be completely converted to a monophenolic 
compound, 3,4-dihydroxyphenylacetic acid within about 3-4 
hours in a prereduced brain-heart infusion broth under 
anaerobic conditions (Winter et al. 1989). Isoflavones are 
analogous to the flavonoids with the aromatic B-ring linked to 
carbon 3 of the C-ring instead of carbon 2. Therefore, it is 
very likely that human intestinal bacteria can also metabolize 
ingested isoflavones to a great extent. This may be why only 
15-20% of isoflavones were recovered intact in urine and 
feces. 
Developing methods to measure monophenolic and other 
diphenolic isoflavone breakdown products may be important 
because some monophenolic compounds like methyl p-
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hydroxyphenylacetate, a metabolite of both exogenous 
flavonoids and tyrosine are inhibitors of hormone-dependent 
cancer cell growth and proliferation. This compound has higher 
affinity for the nuclear type II binding site than estradiol. 
This type II binding site has been suggested to be involved in 
cell growth regulation by estrogenic hormones. This metabolite 
can block estradiol stimulation of uterine growth in vivo and 
inhibit the growth of MCF-7 human breast cancer cells in vitro 
(Markaverich et al. 1988). 
In the future, the cancer-protective potential of 
isoflavones may be estimated from plasma concentrations. Much 
work remains to be done to determine effective plasma 
isoflavone levels. Average plasma concentration of total 
isoflavones reached 4.4 |Jmol/L at 6.5 h after a dose of 2.0 mg 
isoflavones/kg body weight (Table 4). A study of 3T3 cell 
inhibition of production of inositol phosphates (IP), key 
intracellular signals which mediate tumor promotion, showed an 
ICso for daidzein of 8 |Jmol/L and for genistein of 2.2 |imol/L, 
when IP production was stimulated by AlFi" (Higashi and 
Ogawara 1992) . Thus, our data suggest that human dietary 
exposure to isoflavones could provide circulating levels of 
isoflavones that might be of potential benefit with respect to 
cancer development. 
From this study, it was concluded that human absorption, 
excretion and plasma concentration of isoflavones depended 
upon the dose given. Systemic bioavailability of daidzein is 
greater than that of genistein, which suggests that a greater 
focus on the biological effects of daidzein may be warranted. 
Although bioavailability of isoflavones may be, on average, 
only 15%, probably due to a first-pass effect and subsequent 
intestinal bacterial degradation, isoflavones may still be 
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Table 1. Experimental Design 
Subject Feeding 1 > Washout > Feeding 2 > Washout > Feeding 3 
—— (1 day) (2 weeks) (1 day) (2 weeks) (1 day) 
Body Dose mg/kg Dose mg/kg Dose mg/kg 
No. Age Weight mass index body weight body weight body weight 
(kg) (kg/m^) isoflavones isoflavones isoflavones 
1 20 59 . 1 20 .45 2 1 .3 0 .7 
2 21 60, .9 20, .35 1, .3 0 , . 7 2 
3 41 84, .1 26, .84 0, .7 2 1 .3 
4 29 56, .4 22, .31 2 1, .3 0, .7 
5 22 53 . 2 19, .78 1. 3 0 , . 7 2 
6 21 65, , 9 24. 21 0, , 7 2 1. 3 
7 20 52 . ,3 21. .77 2 1. ,3 0 . 7 
8 23 54. , 5 20. ,77 1. ,3 0. , 7 2 
9 19 65. ,4 21. ,36 1. ,3 0 . ,7 2 
10 32 72 . 9 23. , 01 0. 7 2 1. , 3 
11 19 59 . 1 22 . 52 2 1. 3 0 . 7 
12 22 74. 5 26. ,40 1. 3 0. 7 2 
X 24 63.2 22.48 
SD 6.4 9.4 2.20 




0.7 mg/kg 1.3 mg/kg 2 mg/kg 
Intake 
Daidzein(mg) 24 .73 ± 3 .66 45 . 93 + 6 .80 70 . 67 + 10 .46 
Genistein(mg) 19 .29 ± 2 .89 36 .21 ± 5 .36 55 .70 + 8 .25 
Total intake(mg) 44 .28 ± 6 .61 82 .24 + 12 .28 126 . 50 ± 18 . 89 
Urinary excretion (mg) 5 . 93 ± 3 . 47" 14. 87 ± 7 . 65'= 20. 26 + 10. 33^ 
Daidzein recovery (%)'' 19 . +
1 in 00 6. 35 23 . 69 + 9. 71 20. 76 ± 8. 12 
Genistein recovery (%) 5 .29 ± 3 .74 11 . 02 + 6 . 54 10 .04 + 6 .31 
Fecal excretion(mg)^ 0. 79 ± 0 . 97 0 . 96 + 1. 55 2 . 57 + 4 . 78 
% Isoflavone excreted 




1+ 5 . 82 19 .31 + 6 . 97 18 . 05 + 6 .73 
Values are means and SD; n= 12; mg/kg = mg of isoflavones per kg body weight. 
^Urine samples included all the urine in the first 24 hours after dosing and the 
first urination of the second day. 
^For the amount of total urinary isoflavones, the data were log-transformed to 
homogeneity variance before ANOVA. Means and SD of the untransformed data are 
presented in table. Effect of dosage in ANOVA(GLM) was significant (p<0.001). Values 
in a row with different superscripts are significantly different {p<0.05, tukey's 
test). 
''For urinary recovery of isoflavones, effect of kind of isoflavone in ANOVA(GLM) 
was significant (p<0.001). Amount of daidzein urinary recovery was significantly 
greater than that of genistein at each dosage (p<0.05,tukey's test). 
^Fecal samples included all feces excreted before and during fecal marker 
excretion. 
Table 3. Urinary excretion of isoflavones at doses of 0.7 mg/kg, 1.3 mg/kg and 2 
mg/kg^ 
Dosage Isoflavone Time "0" 0-12 Hours 12-24 Hours >24 Hours 
|imol 
0.7 Daidzein^ 0. 04 + 0. 08 14 .48 ± 7.79 4. 52 ± 3 .11 0. ,31 ± 0 . ,28 
mg/kg Genistein 0 . 00 ± 0 . 04 2 .70 + 2 . 96 0 . 93 + 1.55 0 . 15 + 0 . 15 
Total^ 0. 04 + 0. 12= 17 . 20 ± 10.74^ 5 .45 + 4.65'" 0. 46 ± 0. 42= 
1.3 Daidzein^ 0. 08 + 0. 17 30, .44 ± 10 .42 11. 45 ± 9.99 0. 83 ± 1. 06 
mg/kg Genistein ND 10 .44 ± 6.70 3 . 89 + 6.07 0 .44 ± 0 . 93 
Total^ 0. 08 ± 0. 17= 40. 88 + 17.10^ 15. 34 + 17 . 00^= 1. 27 ± 1. 98= 
2 Daidzein^ 0. 31 + 0. 67 42. 21 + 17 .35 14. 20 + 12 . 00 0. 94 ± 1. 02 
mg/kg Genistein 0 .11 + 0 .19 13 .77 + 9.88 6 .18 + 9.77 0 . 67 + 1 . 15 
Total^ 0. 42 ± 0. 85= 55. 98 + 27.15^ 20. ,38 + 2 1 . 1 6 ^  1. 61 + 2 . 15= 
^Values are means and SD; n = 12; mg/kg = mg of isoflavones per kg body weight; 
ND = Not detectable, at a detection limit of 2 ng per 20 jiL injected. 
^For the amount of daidzein and genistein urinary excretion, the data were log-
transformed to homogeneity of variance before ANOVA. Means and SD of the 
untransformed data are presented in the table. Effect of kind of isoflavones in 
ANOVA(GLiM) was significant (p<0.001). The amount of daidzein was significantly 
greater than that of genistein in the same period (p<0.05, Tukey's test). 
^For the total amount of urinary excretion of isoflavones, data were log-
transformed to homogeneity of variance before ANOVA. Means and SD of the 
untransformed data are presented in the table. Effect of measuring time in ANOVA(GLM) 
was significant (p<0.001). Values in a row with different superscripts are 
significantly different (p<0.05, Tukey's test). 
Table 4. Plasma concentration of isoflavones at doses of 0.7 mg/kg, 1.3 mg/kg and 2 
kg/mg^ 
Dosages Isoflavone Time "0" 6.5 Hours^ 24 Hours 
|imol/L 
0.7 Daidzein ND 0 .79 + 0 . 04 0 .04 + 0 . 08 
mg/kg Genistein ND 0 .74 + 0 .44 0 . 07 + 0 . 10 
Total^ ND 1. 53 ± 0. 47 0. 11 + 0. 17 
1.3 Daidzein ND 1 .22 + 0 . 67 0 . 08 + 0 . 08 
mg/kg Genistein ND 1 .07 ± 0 . 63 0 . 19 + 0 .37 
Total^ ND 2 . 29 ± 1. 30 0. 27 + 0. 45 
2 Daidzein ND 2 .24 + 1 . 18 0 . 12 ± 0 . 08 
mg/kg Genistein ND 2 . 15 + 1 .33 0 .26 + 0 .22 
Total^ ND 4. 39 + 2 . 50 0. 38 + 0. 30 
^Values are means and SD; n = 12; mg/kg = mg of isoflavones per kg body weight; 
ND = Not detectable, at a detection limit of 2 ng per 20 fiL injected. 
^For plasma concentration of daidzein and genistein at 6.5 h, data were log-
transformed to homogeneity of variance before ANOVA. Means and SD of the 
untransformed data are presented in the table. Effect of kinds of isoflavone in 
ANOVA(GLM) was not significant (p>0.1). 
^For concentration of total plasma isoflavones, data were transformed to 
homogeneity of variance before ANOVA. Means and SD of the untransformed data are 
presented in the table. Effect of measuring time in ANOVA(GLM) was significant 
(p<0.01). 
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II. BIOAVAILABILITY OF SOYBEAN ISOFLAVONES DEPENDS UPON GUT 
MICROFLORA IN WOMEN^ 
A paper to be published in the Journal of Nutrition 
Xia Xu, Keecha Harris, Huei-Ju Wang, Patricia A. Murphy, and 
Suzanne Hendrich^ 
Abstract 
Soybean isoflavones are proposed to be 
anticarcinogenic, but their effective doses have not been 
established. To study their bioavailability, seven women were 
fed 3.4, 6.9, 10.3 |Jjnol isoflavones/kg body wt in soy milk in 
each of three meals of a liquid diet at one of three feeding 
days. Plasma, urine and fecal isoflavones were measured by 
reverse phase HPLC. In two subjects, fecal isoflavone 
recovery was 10-20 times that in the other five subjects. 
Average 48 h urinary recovery of ingested daidzein and 
genistein was 16±4% and 10±4%, respectively, at all three 
doses among the five subjects excreting only small amounts of 
isoflavones in feces, whereas urinary recovery of daidzein and 
genistein in the two subjects who excreted large amounts of 
fecal isoflavones was 32±5% and 37±6%, respectively. Urinary 
isoflavone excretion was nearly nil in all subjects at 48 h 
after dosing. Average plasma concentration of genistein at 24 
h after the first isoflavone dose in subjects excreting large 
^Reprinted with permission from J. of Nutri. 1995, 125: 0000 -
0000. Copyright © 1995 J. of Nutri. 
^Supported by NIH grant CA-56308-o2, Journal paper No. J-
16107, Iowa Agriculture and Home Economics Experiment Station, 
project no. 3075. 
^Author for correspondence 
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amounts of fecal isoflavones was significantly greater by 
2.5-fold than in subjects who excreted small amounts of 
fecalisoflavones (p<0.05). In vitro anaerobic incubation of 
isoflavones with h\aman feces showed that intestinal half-life 
of daidzein and genistein may be as little as 7.5 h and 3.3 h 
respectively. These data suggest that human isoflavone 
bioavailability depends upon the relative ability of gut 
microflora to degrade these compounds. 
Introduction 
The isoflavones, daidzin, genistin and their aglycones 
daidzein and genistein, are abundant in soy foods (0.2-1.5 
mg/g) (Wang and Murphy 1994). Isoflavones are antioxidants in 
vitro and in vivo, inhibiting P-carotene bleaching and fat 
rancidity (Pratt and Birac 1979), and increasing rat hepatic 
cytosolic glutathione peroxidase activity (Hendrich et al. 
1994). Isoflavones are also antiestrogens, enhancing sex 
hormone binding globulin (Adlercreutz et al. 1987) and 
inhibiting human preadipocyte aromatase (an estrogen synthase) 
(Adlercreutz et al. 1993). Dietary isoflavone intake might 
partly explain why Japanese consuming a traditional diet rich 
in soyfoods have low breast cancer incidence and mortality 
(Adlercreutz et al. 1991). Rats consuming a soy-based diet 
develop fewer mammary tumors following administration of the 
carcinogens N-methylnitrosourea and 7,12-dimethylbenz[a]-
anthracene than rats on isonitrogenous and isocaloric diets 
without soy (Barnes et al. 1990). 
The anticarcinogenic effect of soy may be due to 
isoflavones. Genistein inhibits the growth of estrogen 
receptor-negative or -positive human breast cancer cell lines 
(concentration for 50% inhibition of cell growth (ICso) =24-44 
}lmol/L; Peterson and Barnes 1991) . Genistein and daidzein (ICso 
of 2.2 |imol/L and 8 |imol/L respectively) can inhibit 
production of inositol phosphates, key intracellular signals 
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of proliferation stimulated by aluminum tetrafluoride in 3T3 
cells (Higashi and Ogawara 1992). Genistein also blocks in 
vitro angiogenesis, another proposed mechanism of 
anticarcinogenesis (ICso of 150 |imol/L, Fotsis et al. 1993). 
These findings suggest that isoflavones in soybean foods 
might play an important role in hioman health maintenance. A 
previous human feeding study showed that absorption of a 
single dose of isoflavones from soy milk fed in a controlled 
liquid diet was dose dependent (Xu et al. 1994). Average 24 h 
urinary recovery of daidzein and genistein was 21% and 9%, 
respectively, at doses of 2.7, 5.0 and 7.7 |ainol isoflavones/kg 
body weight. Average plasma total isoflavone concentration was 
4.4 jimol/L at 6.5 h after a dose of 7.7 |imol isof lavones/kg 
body wt. Soymilk isoflavones seemed to be 85% degraded in the 
intestine. To further characterize the bioavailability of soy 
isoflavones and assess the potential for human gut microflora 
metabolism and degradation of isoflavones after ingestion, a 
group of adult females received three soymilk meals per day in 
a well-controlled liquid diet. In vitro anaerobic incubation 
of isoflavones with human feces was also performed. Isoflavone 
content of plasma, urine, fecal samples were measured. 
Materials and methods 
Subjects and Protocol 
The subjects were seven adult females between 2 0 and 41 
years of age, with body weight of 61.9 ± 11.3 kg and body mass 
index (BMI) of 22.0 ± 2.4 kg/m^. 
All the subjects were in good health, based on 
examinations performed by Student Health Center physicians at 
Iowa State University (ISU). Subjects did not use medication 
before and during the study. The procedures for this feeding 
study were approved by the Human Subjects Committee of ISU. 
Informed consent of subjects was obtained in writing. All 
subjects were omnivorous. 
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The study consisted of three feeding days, each separated 
by a two-week washout period. Each subject consumed 3.4, 6.9 
and 10.3 |lmol/kg body wt total isoflavones from soy milk 
powder. Each dose was consumed three times in nutritionally 
complete liquid meals on each feeding day (10.2, 20.7 and 3 0.9 
|imol total isoflavones/ kg body wt per day) beginning at 7:00 
am, with lunch and dinner fed at five hour intervals after 
breakfast. Subjects were randomly assigned to doses in a 
cross-over design. Each meal contained soy milk powder 
reconstituted with distilled water (Now Foods, Inc., Glendale 
Hts. , IL) mixed with chocolate-flavored Carnation Instant 
Breakfast® (Nestle Food Company, Glendale, CA) diluted with 
whole cow's milk. Total caloric intakes fed were based upon 
subjects' energy requirements, according to the Recommended 
Dietary Allowances tables (Food and Nutrition Board, National 
Research Council, 1989). Subjects were instructed not to 
consume anything for 10 h before dosing, and not to eat 
anything other than what was given on the feeding day. They 
were also asked not to eat any soybean foods or foods 
containing texturized vegetable protein, hydrolyzed vegetable 
protein, or soy protein isolate during the washout periods. A 
list of such foods was provided. No adverse effects such as 
diarrhea were reported after soymilk dosing. 
Biological Sample Collection 
Blood samples. Venous blood samples (5 mL) were collected in 
heparinized vacuum containers by medical technologists under 
stringent aseptic conditions at the Student Health Center, ISU. 
A blood sample was collected within 1 h before dosing (Time 
"0"). Blood samples were also collected at 6.5 and 24 h after 
dosing. Samples were centrifuged within one hour after 
collection at 3000 x g for 20 minutes at 4°C (Model 4D; 
International Equipment Co., Needham Hts., MA), and plasma was 
stored in a -20°C freezer. 
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Urine saxaples. For each subject, a urine sample was collected 
in the morning before dosing (Time "0"). All urine was 
collected and pooled in four 12 h increments during the first 
48 h after dosing. The first urination of the third day after 
dosing was also collected. After recording the total volume, 
50 mL of each of the six samples was stored in a -20°C 
freezer. 
Fecal samples. Capsules containing 1 g carmine red 
(Pharmaceutical Service, University of Iowa, Iowa City, lA) 
were given with the soymilk. One fecal sample from each 
subject was collected before soymilk feeding (Time "0"). After 
dosing, all feces excreted before and during fecal marker 
excretion were collected. Usually, the fecal marker appeared 
in feces one or two days after dosing. Fecal sample collection 
was stopped when fecal marker no longer appeared in feces. 
After collecting the fecal samples, feces were freeze dried. 
After recording the weights of dry samples, feces were ground 
to a fine powder in a coffee mill (Braun Company Inc., 
Lynnfield, MA). Ten g of each dry fecal sample was stored in a 
-20°C freezer until analysis. 
Soybean Milk Powder Analysis 
The concentrations of total isoflavones in both soymilk 
powder and chocolate-flavored Carnation Instant Breakfast® 
were measured as free isoflavones after hydrolysis in 1 mol/L 
HCL at 98°C following the method of Wang et al. (1990) . The 
method of HPLC analysis was as described by Wang and Murphy 
(1994). 
Biological Sample Analysis 
Plasma and urine samples. Sample preparation for plasma and 
urine isoflavone analysis was performed according to the 
methods described by Lundh et al. (1988). Plasma and urine 
samples were treated with glucuronidase/ sulfatase (Sigma 
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Chemicals Company, St. Louis, MO) to produce the parent 
isoflavones. Chromatographic analysis followed the conditions 
described by Xu et al.(1994). Samples were automatically 
injected with a Spectra-Physics Autosampler Model 87 80XR 
(Spectra-Physics, Fremont, CA). Two Beckman Model llOB pumps 
(Beckman Instruments, Inc., Berkeley, CA), and one Beckman 
Model 420 Microprocessor solvent flow controller were used. 
Beckman Model 163 variable wavelength detector set at 254 nm 
was connected with Beckman Model 427 Integrator by which 
chromatographic data were calculated and plotted. 
Daidzein (4',7-dihydroxyisoflavone) was obtained from 
Life Science Group, ICN Pharmaceuticals, Inc., Plainview, NY. 
Genistein (4',5,7-trihydroxyisoflavone) was obtained from 
Calbiochem Corporation, La Jolla, CA. Equol (4',7-
dihydroxyisoflavondiol) was a generous gift from Dr. H. 
Adlercreutz (Department of Clinical Chemistry, University of 
Helsinki, Finland). 
A series of standards (1, 2, 4, 8, 12, 15 and 24 |imol/L) 
were assayed to quantify isoflavones. For each subject, plasma 
and urine samples were spiked randomly with daidzein, 
genistein and equol standards (0.15 |lg isoflavone/100 |IL added 
to each sample) to measure recovery. 
Fecal samples. Sample preparation and analysis were 
performed as described by Xu et al.(1994). To ensure the 
quality of analysis, a series of standards (1, 2, 4, 8, 12, 16 
and 24 |imol/L) and fecal samples spiked with 500 |IL of 32 
|imol/L daidzein, genistein and equol standards were analyzed 
to measure recovery. 
In vitro incubation of isoflavones with human fecal flora 
Daidzein and genistein standards were dissolved in 
sterilized brain-heart infusion broth (DIFCO Laboratories, 
Detroit, MI) at concentrations of 600 |imol/L. The solution was 
kept at 4°C until use. Twice within a 4 wk period, 20 g of 
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freshly voided feces from one 31 year-old, 7 6 kg male subject 
(BMI=22.5) collected in a sterile container was added to 180 
mL of sterilized brain-heart infusion broth, and then 
homogenized by Stomacher Lab-Blender 400 (Tekmar® Company, 
Cincinnati, OH) under anaerobic conditions. Homogenate was 
quickly transferred to 50 mL sterile tubes and centrifuged at 
3000 X g for 5 minutes at ambient temperature. The supernatant 
was used for the experiment. Four mL of freshly made 
supernatant was added to sterile tubes containing 1 mL of 600 
|imol/L daidzein or genistein. Four ml sterile brain-heart 
infusion broth was added to two sterile tubes containing 1 ml 
isoflavone standard solution as controls. Final concentration 
of both daidzein and genistein in each tube was 120 |iinol/L. 
Tubes were incubated at 37°C in a Gas-Pak® anaerobic 
incubation jar (Fisher Scientific, Pittsburgh, PA) filled with 
N2 gas. Two tubes were taken out at 6, 12, 18 and 24 h and at 
8 h interval until 96 h. The two control samples were taken 
out after 96 h incubation. The incubator was recharged with Nj 
gas each time samples were taken. Two ml samples were injected 
onto pre-wetted Waters Sep-Pak Cia cartridges (Millipore, 
Milford, MA). The cartridges were washed with 2 ml Waters 
milli-Q water twice, and 2 ml 80% methanol to elute the 
isoflavones. All samples were analyzed by the same reverse 
phase HPLC system as for fecal sample analysis (Xu et al. 
1994). Four ml of freshly made homogenate supernatant was also 
added to four sterilized tubes containing 1 ml isoflavone 
standard solution and assayed for isoflavones immediately to 
measure recovery. 
Statistical Methods 
Statistical analysis was performed with the Statistical 
Analysis System (SAS Institute, Inc., Cary, NC) version 6.06 
on the Iowa State University mainframe computer. Data were 
tested for heterogeneity of variance. If necessary, data were 
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transformed to homogeneity before ANOVA (Snedecor and Cochran 
1989). Analysis of variance (general linear models) was 
performed on the data obtained from the human feeding 
experiment. Subjects and feeding times were treated as blocks. 
The effects of dosage, time, and type of isoflavones as well 
as subject and feeding time upon plasma concentration, urinary 
and fecal excretion of isoflavones were determined. If the 
effect from any one of these factors other than the type of 
isoflavones was significant, Tukey's test was used for 
comparison of means within the factor. Meanwhile, the 
difference of isoflavone plasma concentration, urinary and 
fecal recovery between low and high isoflavone fecal excretors 
was tested by using the mean square for subjects within the 
type of fecal excretion as the error term. A p value of 0.05 
or less was considered to be significant. 
Results 
Soymilk powder contained 4.7 9±0.31 |imol total 
isoflavones/g (44% genistein and 56% daidzein). No isoflavones 
were detected in chocolate-flavored Carnation Instant 
Breakfast®. 
Fecal recoveries of daidzein and genistein were only 0.7% 
and 0.4% of the ingested amount, respectively, among five 
subjects (Table 1). In contrast, fecal recoveries of daidzein 
and genistein were about 6% and 7% of the ingested amount, 
respectively, in subjects 3 and 5. Their average fecal 
recoveries of daidzein and genistein at all three isoflavone 
doses were significantly greater than those among the five 
subjects excreting small amounts of isoflavones (p<0.01) . 
For five subjects excreting small amounts of fecal 
isoflavones (Table 2), average 48 h urinary recovery of 
daidzein and genistein was about 16% and 10%, respectively, at 
each dose. Urinary recovery of daidzein was significantly 
greater than that of genistein (p<0.01). For two subjects 
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excreting large amounts of fecal isoflavones, average 48 h 
urinary recovery of daidzein and genistein was about 34% and 
3 8%, respectively, at each dose. Urinary daidzein and 
genistein recoveries in subjects excreting large amounts of 
fecal isoflavones was significantly greater than those among 
subjects excreting small amounts of fecal isoflavones at each 
dosage (p<0.05) . No equol was found in plasma, urine and fecal 
samples although the recovery of equol was between 64-7 5% in 
all samples tested. 
At all three doses, the amount of urinary isoflavones 
among subjects excreting small amounts of fecal isoflavones 
was significantly greater in the first and second 12 h after 
dosing than at other time points (p<0.05) (Table 3). After 48 
h, urinary excretion of isoflavones was nearly nil. The amount 
of urinary daidzein was significantly greater than that of 
genistein during the first 24 h (p<0.001). Among the two 
subjects excreting large amounts of fecal isoflavones, the 
greatest amount of urinary isoflavones was found in the second 
12 h (Table 4). Although the amount of urinary daidzein was 
greater than that of genistein in the first 24 h after dose, 
in the second 24 h, the amount of urinary genistein was 
greater than that of daidzein. In these two subjects, urinary 
excretion of isoflavones was also almost nil at 48 h after 
dosing. 
Among the five subjects excreting small amounts of fecal 
isoflavones, plasma concentration of daidzein and genistein 
was significantly increased at 5.5 h after dosing compared 
with the concentration at other times (p<0.05), although at 
twenty-four hours after dosing plasma concentration of 
isoflavones was still about half or two-thirds of the level at 
6.5 h (Table 5). The plasma concentration of daidzein was 
significantly greater than that of genistein (p<0.05) at 6.5 
and 24 h after dosing. The average plasma concentration of 
both daidzein and genistein increased significantly with 
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increasing dose (p<0.05). Among the two subjects excreting 
large amounts of fecal isoflavones, plasma concentration of 
genistein at 24 h was significantly greater than that among 
the five subjects excreting small amounts of fecal isoflavones 
at each dosage (p<0.05) (Table 5). 
During four days of anaerobic incubation of human feces, 
daidzein and genistein completely disappeared after 72 h and 
18 h respectively (Figure 1). The loss of isoflavones seemed 
to follow first-order kinetics, with the half-lives of 
daidzein and genistein estimated at 7.5 h and 3.3 h 
respectively. After 18 h incubation some new peaks appeared, 
accompanying the loss of genistein and daidzein (Figure 2). No 
loss of isoflavones was observed in control samples. 
Isoflavone recoveries in samples tested ranged from 93-98%. 
Discussion 
This study may provide insight into the nature of 
gastrointestinal absorption of soy isoflavones. On the 
average, soybean milk powder only contains about 4-5% of total 
isoflavones as the aglycones, daidzein and genistein (Wang and 
Murphy 1994) . The glycosides of flavonoids and isoflavones are 
very poorly absorbed in the small intestine compared with 
their aglycones because of the glycosides' higher 
hydrophilicity and greater molecular weight (Brown 1988). On 
the average, gastric emptying time after 500-600 mL of a 
complete liquid meal which has similar volume and content as 
our subjects received is about 1 h in humans (Davenport 1982) . 
The average length of transit time of such a meal is about 5 
min in the duodenum, 2 h in the jejunum, and 3-6 h in the 
ileum (Welling 1986). In our study, average plasma 
concentrations of isoflavones at 6.5 h after breakfast dose 
(1.5 h after lunch dose) were 3.6 and 6.7 Umol/L, 
respectively, at doses of 3.4 and 6.9 |imol isoflavones/kg body 
weight per meal (Table 5). However, at 6.5 h after a single 
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breakfast dose of 5.0 and 7.7 [imol isoflavones/kg body weight, 
average plasma concentration of isoflavones was only 2.3 and 
4.4 luUnol/L, respectively, in our previous report (Xu et al. 
1994). Since human subjects in both studies were given the 
same controlled liquid diet, some of the isoflavones consumed 
at 'lunch very likely already entered the general circulation 
at 1.5 h after lunch. This suggested that the absorption of 
soybean isoflavones in humans might begin in the proximal 
small intestine since surface area and blood perfusion rate 
strongly favor more efficient absorption from the proximal 
small intestine than from the stomach (Welling 1986). This is 
problematic because isoflavones are present primarily as P-
glucosides in soybean foods, which are poorly hydrolysed by 
mammalian intestinal digestive enzymes (Brown 1988). 
Glucosidases of intestinal microflora in lower bowel can 
liberate aglycones and promote their absorption (Friend and 
Chang 1984) . But gastric hydrochloric acid might also produce 
isoflavone aglycones by the same mechanism used in soybean 
food analysis. Thus, absorption of soymilk isoflavones as 
aglycones might begin in the proximal small intestine. 
Human intestinal bacteria can metabolize and degrade 
isoflavones as well as liberate isoflavone aglycones. Although 
several groups of bacteria possess p-glucosidase activity, 
Lactobacilli, Bacteroid.es and Bifidobacteria play major roles 
in the intestinal hydrolysis of numerous plant p-glucosides 
present in the human diet such as glucosides of flavonoids and 
isoflavones to produce aglycones (Hawksworth et al. 1971). 
From proximal to distal small intestine, the amount of 
bacteria is increased from very low bacterial numbers in the 
upper 1/3 of small intestine to almost "colon-like" resident 
flora in the lower 1/3 of small intestine (Heneghan 1988). 
Contents of both distal small intestine and large intestine in 
humans have substantial amount of Lactobacilli, Bacteroides 
and Bifidobacteria, and the number of each of three bacterial 
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groups is about 10^-10"^ bacteria per g wet weight (Gorbach et 
al. 1967 and Mitsuoka 1982). Whereas, contents of the human 
proximal small intestine contain almost none of these bacteria 
(Mitsuoka 1982). Some bacteria in human large intestine also 
have p-glucuronidase and arylsulfatase which can liberate 
aglycones from conjugates of liver phase II biotransformation 
(Heneghan 1988). On the other hand, certain strains of 
Clostridia in human lower gastrointestinal tract can cleave 
the C-ring of many flavonoids, such as guercetin (3,3',4',5,7-
pentahydroxyflavone), kaempferol (3,4',5,7-
tetrahydroxyflavone), naringenin (4',5,7-trihydroxy 
flavanone), and produce monophenolic compounds anaerobically 
(Winter et al. 1989). Flavonoids are analogous to the 
isoflavones, with the aromatic B-ring attached to carbon 2 of 
the C-ring instead of carbon 3. Interestingly, Clostridia are 
not present in all individuals' feces although their average 
number is about 10^-10^° bacteria per g wet feces (Mitsuoka 
1982). Rat intestinal microflora can also cleave the C-ring of 
flavonoids and isoflavones in vitro (Griffiths and Smith 
1972), and germ-free rats did not excrete C-ring fission 
products in urine compared with conventional rats after 
aglycones were fed (Griffiths and Barrow 1972). 
The bacteria in the gastrointestinal tract play an 
important role in determining the magnitude and pattern of 
isoflavone bioavailability. When four human subjects orally 
received 4 g quercetin, about 50% of the dose was not 
recovered in urine and feces after 72 h, and the remainder of 
the dose was thought to have been degraded microbially in the 
human lower bowel (Gugler et al. 1975) . Human intestinal 
bacteria can completely convert 5 mg of quercetin to a 
monophenolic compound, 3,4-dihydroxyphenylacetic acid within 
about 3-4 hours anaerobically in a prereduced brain-heart 
infusion broth (Winter et al. 1989). Our in vitro fecal 
incubation (Figure 1) also suggested that human intestinal 
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bacteria might metabolize and degrade ingested soybean 
isoflavones to a great extent. This may be why only 14-43% of 
isoflavones were recovered intact in urine and feces (Tables 
1 ,  2 )  .  
In our study, five of the seven subjects only excreted 
0.4-0.7% of ingested isoflavones intact in feces (Table 1), 
whereas 6-8% of ingested isoflavones were excreted intact in 
feces in the other two subjects. This difference in fecal 
excretion of isoflavones seemed to profoundly alter isoflavone 
bioavailability reflected in urinary recovery of ingested 
isoflavones, which was more than twice as great in high versus 
low fecal excretors (Table 2). A model of human isoflavone 
disposition following oral dosing was proposed by Xu et al. 
(1994). After absorption isoflavones are extensively 
transformed by phase II enzymes, especially, by 
glucuronidation (Axelson et al. 1984). Isoflavones then 
undergo rapid urinary and biliary excretion in rats (Axelson 
and Setchell 1981), and humans (Rondelli et al. 1991) . In 
humans the molecular weights of isoflavones are probably 
within the range which enables their conjugates to undergo 
partitioning between bile and urine. Gut bacterial 
deconjugating enzymes (i.e., p-glucuronidases and 
arylsulfatases) can hydrolyze the isoflavone conjugates to 
produce aglycones. Isoflavones also are extensively 
metabolized and degraded by intestinal microflora, which 
prohibit their reabsorption from lower bowel. If for any 
reason these bacteria were not effective in degradation and 
metabolism of isoflavones, more isoflavones would be absorbed. 
These might explain the strong association between high fecal 
isoflavones and greater total urinary recovery of isoflavones. 
Isoflavones and flavonoids which possess a 5-OH group, 
such as genistsin and not daidzein, are much more susceptible 
to C-ring cleavage by rat intestinal bacteria (Griffiths and 
Smith 1972) . Consistent with this, our in vitro incubation 
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study indicates that the human intestinal half-life of 
genistein may be less than half of that for daidzein (Figure 
1). Therefore, less genistein than daidzein can be absorbed. 
This may be why subjects excreting small amounts of fecal 
isoflavones had less urinary recovery and lower plasma 
concentration of genistein than those of daidzein (Tables 2, 
5), although the soymilk fed contained similar amounts of 
daidzein and genistein. When intestinal bacterial degradation 
of isoflavones, especially of genistein is limited, greater 
amounts of genistein than daidzein can be found in urine and 
plasma of the two subjects excreting relatively large amounts 
of fecal isoflavones (Tables 4, 5). 
Cancer protective effects of isoflavones may be 
contributed by isoflavones and their metabolites, because some 
monophenolic compounds like methyl p-hydroxyphenylacetate, a 
metabolite of both exogenous flavonoids and tyrosine are 
inhibitors of hormone-dependent neoplastic cell proliferation. 
This compound has higher affinity for the nuclear type II 
binding site than estradiol. This type II binding site has 
been suggested to be involved in cell growth regulation by 
estrogenic hormones. This metabolite can block estradiol 
stimulation of uterine growth in vivo and inhibit the growth 
of MCF-7 human breast cancer cells in vitro (Markaverich et 
al. 1988). In our in vitro incubation, the appearance of new 
peaks in the chromatogram after 18 h of incubation (Figure 2), 
accompanying the loss of genistein and daidzein indicate the 
possible existence of isoflavone metabolites that deserve 
further chemical and biological characterization. These new 
peaks are not equol because the retention time for equol in 
our reverse phase HPLC system is between daidzein and 
genistein (Xu et al. 1994). Developing methods to measure 
monophenolic and other diphenolic isoflavone breakdovm 
products may be important. 
In the two subjects excreting large amounts of fecal 
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isoflavones, plasma concentration of genistein at 24 h after 3 
doses of 10.3 |imol/kg isoflavones were fed was still about 
5.07 |imol/L, about twice as much as that among subjects 
excreting small amounts of fecal isoflavones (Table 5). A 
study of 3T3 cell inhibition of production of inositol 
phosphates, key intracellular signals which mediate tumor 
promotion, showed an ICso for daidzein of 8 |imol/L and for 
genistein of 2.2 |imol/L, when inositol phosphate production 
was stimulated by aluminum tetrafluoride (Higashi and Ogawara 
1992). Thus, our data suggest that enhancement of 
anticarcinogenic activity of isoflavones may be expected among 
subjects with relatively great fecal recovery of ingested 
isoflavones or exhibiting longer isoflavone intestinal half-
life. Alteration of gut microbial function to prevent 
isoflavone degradation might enhance the anticarcinogenic 
potential of isoflavones. 
From this study, it was concluded that human absorption, 
excretion and plasma concentration of isoflavones depended 
upon dose. It is reasonable to infer that the condition of 
intestinal microflora profoundly influences isoflavone 
bioavailability. Although bioavailability of isoflavones may, 
on average, vary from 13% to 3 5% depending upon the 
individual's gut microflora, isoflavones may still be absorbed 
enough from soymilk to exert potentially beneficial biological 
effects. 
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Figure 1: In vitro incubation of isoflavones with human feces 
Anaerobic incubation of 1 itiL 600 |iinol/L daidzein and 
genistein with 4 mL supernatant from homogenate of prereduced 
brain-heart infusion broth and freshly voided feces of a 
healthy human volunteer at 37oc. Concentration of daidzein and 
genistein was measured by a reverse phase HPLC system at 6, 
12, 18, 24 h and 8 h interval until 95 h after incubation. 
Data of Log concentration and hours of incubation were 
plotted. The loss of isoflavones seem to follow first-order 
kinetics, with the loss of genistein occurring at a much 
faster rate than daidzein. Half-lives of daidzein and 




Figure 2: HPLC chromatogram of incubated samples 
HPLC chromatogram after 12 h (A) and 18 h (B) of anaerobic 
incubation as described in Figure 1. Dein= daidzein, Gein= 
genistein, and X= unknown peak. The same reverse phase HPLC 
system as for fecal sample analysis (Xu et al. 1994) was used 
to determine and quantify isoflavones. Comparing A and B, 
after 18 h incubation unknown peak X was increased, 
accompanying the loss of genistein and daidzein. 
Table 1. Human fecal isoflavone recovery after three doses of 3.4, 6.9 or 10.3 
|jmol/kg body wt^ 
Isoflavones 3 .4 |lmol/kg 6. 9 fimol/kg 10.3 |imol/kg 
Subjects excreting small % 
amounts of isoflavones" 
Daidzein recovery 0. 55 ± 0.22 0.72 ± 0.18 0.82 ± 0.41 
Genistein recovery 0 .29 + 0.16 0.46 ± 0.29 0.49 ± 0.31 
Totcil recovery 0 .44 ± 0.18 0.61 ± 0.22 0.69 ± 0.36 
Subjects excreting large 
amounts of isoflavones^ 
Daidzein recovery'' 5. 98 ± 2 . 67 5.02 ± 2.13 5.50 ± 2.78 
Genistein recovery® 8. 59 + 0.32 5.92 ± 0.21 6.39 ± 1.02 
Total recovery 7 .62 + 1.51 5.50 ± 1.17 6.01 ± 1.89 
^Fecal samples included all feces excreted before and during fecal marker 
excretion. 
^Subjects excreting small amounts of isoflavones included subjects 1, 2, 4, 6 and 
7. Values are means and SD; n = 5. 
^Subjects excreting large amounts of isoflavones included subjects 3 and 5. 
Values are means and SD; n = 2. 
^ ^Data were log-transformed to achieve homogeneity of variance before ANOVA. 
Means and SD of the untransformed data are presented in the table. Fecal recoveries 
of daidzein and genistein in two subjects excreting large amounts of fecal 
isoflavones was significantly greater than those of daidzein and genistein among five 
subjects excreting small amounts of fecal isoflavones at each dosage, by ANOVA 
(general linear models) with mean square for subjects within the type of fecal 
excretion as error term (p< 0.01). 
Table 2. Human 48 h urinary isoflavone recovery after three doses of 3.4, 6.9 or 
10.3 |imol/kg body wt^ 
Isoflavones 3.4 ^imol/kg 6.9 |imol/kg 10.3 |Jmol/kg 
Subjects excreting small 




17.22 + 4.19 
10.31 ± 4.08 
14.17 ± 4.13 
15.21 ± 3.04 
9.96 ± 4.14 
12.90 ± 3.87 
15.97 ± 4.26 
10.49 ± 4.03 
13.56 ± 4.16 
Subjects excreting large 




33.06 ± 5.65 
38.68 ± 4.08 
35.53 ± 4.87 
31.46 ± 4.56 
36.77 ± 6.14 
33.80 + 5.52 
30.31 ± 6.05 
35.61 ± 6.29 
33.04 ± 6.23 
^Urine samples included all the urine excreted during the first 48 hours after 
dosing and the first urination of the third day. 
^Subjects excreting small amounts of isoflavones included subjects 1, 2, 4, 6 and 
7. Values are means and SD; n = 5. 
^The urinary recovery of daidzein was significantly greater than that of 
genistein at each dosage by ANOVA (general linear models) (p<0.01). 
^Subjects excreting large amounts of isoflavones included subjects 3 and 5. 
Values are means and SD; n = 2. 
® ""Urinary recoveries of daidzein and genistein in two subjects excreting large 
amounts of fecal isoflavones was significantly greater than those of daidzein and 
genistein among five subjects excreting small amounts of fecal isoflavones at each 
dosage, by ANOVA (general linear models) with mean square for subjects within the 
type of fecal excretion as error term (p< 0.05). 
Table 3. Urinary excretion of isoflavones during and after three doses of 3 . 4 ,  6 . 9  
and 10.3 |imol/kg body wt in subjects excreting small amounts of fecal 
isoflavones^ 
Time "0" 0-12 h 12-24 h 24-36 h 36-48 h >48 h 
|imol 
3.4 (imol/kg 
Daidzein^ 0.12±0.16 30.46+ 7.39 27.16± 9.35 2.04± 1.89 0.47±0.94 0.16±0.16 
Genistein ND 10.88± 4.51 12.91± 4.48 2.04+ 1.81 0.89±1.15 0.07±0.07 





















Daidzein^ 0.7511.38 85.24+33.92 60.84+27.98 16.07±11.32 4.6015.34 0.35±1.10 
Genistein 0.37±0.48 30.45111.69 34.78+26.83 9.29+ 7.18 5.7719.03 0.89+0.93 
Total' 1.1211.86"= 115 . 69 + 45 . 61^ 95 . 62±54 . 81^ 25 . 36±18 . 50'= 10 . 37±14 . 37*= 1. 24±2 . 03"= 
Values are means and SD; n = 5; |imol/kg = ^imol of isoflavones per kg body 
weight; ND = Not detectable, at a detection limit of 2 ng per 20 |iL injected. 
"To compare excretion of the two isoflavones, the data were log-transformed to 
achieve homogeneity of variance before ANOVA. Means and SD of the untransformed data 
are presented in the table. The amount of daidzein was significantly greater than 
that of genistein at first 24 h, by ANOVA(general linear models) (p<0.001). 
'To compare excretion of total isoflavones at different times after dosing, data 
were log-transformed to achieve homogeneity of variance before ANOVA. Means and SD of 
the untransformed data are presented in the table. Effect of time was significant by 
ANOVA (general linear models) (p<0.001), and values noted by different superscripts 
are significantly different (p<0.05, Tukey's test). 
Table 4. Urinary excretion of isoflavones during and after three doses of 3.4, 6.9 
and 10.3 fimol/kg body wt in subjects excreting large amounts of fecal 
isoflavones^ 
Time "0" 0-12 h 12-24 h 24-36 h 36-48 h >48 h 
jimol 
3 . 4 fimo 1 / kg 
Daidzein 0.43±0.43 43.47± 4.44 68.46+13.79 18.90± 2.40 4.60± 1.85 0.47±0.12 
Genistein ND 32.38± 7.96 49.21±20.28 25.23+11.43 10.03± 6.36 1.15±0.85 
Total 0.43+0.43 75.85±12.40 117.67±34.07 44.13±13.87 14.63± 8.21 1.6210.97 
6.9 |imol/kg 
Daidzein ND 94.04+ 8.53 114.36±18.98 38.99+13.13 11.83± 7.51 0.24+0.24 
Genistein ND 61.16± 8.33 91.76±30.56 47.62±19.76 23.79± 8.10 ND 
Total ND 155.20±16.86 206.12+49.54 86.61±32.89 35.62115.61 0.2410.24 
10.3 |lmo 1 / kg 
Daidzein 1.5311.53 125.84+29.51 166.00+37.30 61.82114.66 18.75111.24 1.1010.55 
Genistein ND 92.02125.75 124.28140.55 70.63114.80 36.78125.42 2.1810.33 
Total 1.5311.53 217.86155.26 290.28177.85 132.45129.46 55.53+36.66 3.2810.88 
H^ 'alues are means and SD; n = 2; |imol/kg = jimol of isoflavones per kg body 
weight; ND = Not detectable, at a detection limit of 2 ng per 20 |IL injected. 
Table 5. Plasma concentration of isoflavones during and after three doses of 
3.4, 6.9 and 10.3 |imol/kg body wt 
Time "0" 6.5 h 24 h 
Subjects excreting small [imol/L 
amounts of isoflavones^ 
Dose 
3.4 Daidzein^ ND 1. 88 + 0. 46 0 . 94 + 0. 34 |imo 1 / kg Genistein ND 1 . 43 + 0 . 41 0 . 53 ± 0 .30 
6.9 Daidzein^ ND 3 . 62 + 0. 72 2 . 04 + 0. 63 |imol/kg Genistein ND 2 .78 ± 0 .75 1 . 15 ± 0 .46 
10.3 Daidzein^ ND 5. 28 + 1. 07 3 . 04 ± 0. 80 |imol/kg Genistein ND 4 . 59 ± 1 .35 2 . 17 ± 0 .75 
Subjects excreting large 
amounts of isoflavones^ 
Dose 
3.4 Daidzein^ ND 1. 92 1 . 16 |imol/kg Genistein^ ND 2 . 03 1 . 92 
6.9 Daidzein^ ND 3. 84 3 . 00 |imol/kg Genistein^ ND 3 . 15 3 .00 
10 .3 Daidzein"* ND 6. 08 3 . 60 
fimol/kg Genistein^ ND 6. 00 5 . 07 
^Subjects excreting small amount of isoflavones included subjects 1, 2, 4, 6 and 
7. Values are means and SD; n = 5; |imol/kg = |imol of isoflavones per kg body weight; 
ND = Not detectable, at a detection limit of 2 ng per 20 |J.L injected. 
continued 
continued, Table 5 
^To compare plasma concentration of two isoflavones, data were log-transformed to 
achieve homogeneity of variance before ANOVA. Means and SD of the untransformed data 
are presented in the table. Plasma concentration of daidzein was significantly-
greater than that of genistein at 6.5 and 24 h after dosing, by ANOVA (general linear 
models) {p<0.05). 
^Subjects excreting large amount of isoflavones included subjects 3 and 5. Values 
are means; n=2. 
''To compare plasma concentration of daidzein between low and high fecal 
isoflavone excretors at each dosage, data were log-transformed to achieve homogeneity 
of variance before ANOVA. Means and SD of the untransformed data are presented in the 
table. Plasma concentrations of daidzein between low and high fecal isoflavone 
excretors were not significantly different at both 6.5 h and 24 h after dosing, by 
ANOVA (general linear models) with mean square for subjects within the type of fecal 
excretion as error term (p>0.1). 
^To compare plasma concentration of genistein between low and high fecal 
isoflavone excretors at each dosage, data were log-transformed to achieve homogeneity 
of variance before ANOVA. Means and SD of the untransformed data are presented in the 
table. Plasma concentrations of genistein between low and high fecal isoflavone 
excretors were significantly different at 24 h after dosing (p<0.05), but not at 6.5 
h after dosing (p>0.1) by ANOVA (general linear models) with mean square for subjects 
within the type of fecal excretion as error term. 
77 
III. NEITHER DIET SELECTION NOR TYPE OF SOY FOOD 
SIGNIFICANTLY AFFECT ISOFLAVONE BIOAVAILABILITY^ 
A paper to be submitted to the Journal of Nutrition 
Xia Xu, Huei-Ju Wang, Patricia A. Murphy, and 
Suzanne Hendrich^ 
Abstract 
To characterize the effect of background diet and 
soyfood form upon bioavailability of soybean isoflavones, 
proposed anticarcinogenic food components, eight adult women, 
ages 20-41, were fed 0.9 mg isoflavones/kg body wt from 
soymilk in three meals for a day. Each subject consumed a 
basic foods diet at 7:30 am, 12:30 pm and 5:30 pm, a self-
selected diet at these same times, or an ad libitum diet with 
the soymilk. In a second study, single isoflavone doses of 
0.8-1.4 mg/kg were fed in breakfast casseroles containing 
tofu, tempeh, soybeans or texturized vegetable protein. Both 
studies employed a randomized cross-over design. There was a 
one-week washout period between soy doses. Plasma, urine and 
fecal isoflavones were measured by reverse-phase HPLC. With 
basic, self-selected, and ad libitum diets, 48 h urinary 
recovery of daidzein was 27±8%, 26±10% and 26±9%, 
respectively, and of genistein, 20+7%, 18+9%, and 18±8%, 
respectively. Recoveries of daidzein in urine over 24 h from 
cooked soybean, texturized vegetable protein, tofu, and tempeh 
were 46+16%, 51±10%, 50±10%, and 38±18%, respectively, and of 
" Supported by NIH grant"CA-56308-02, Journal paper No. J- , 
Iowa Agriculture and Home Economics Experiment Station, 
Project No. 3 075, and the Center for Designing Foods to 
Improve Nutrition, Iowa State University, Ames, lA 50011. 
^ Author for correspondence 
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genistein, 13±6%, 14±8%, 16±5%, and 9±4%, respectively. In 
both studies, urinary recovery of daidzein was greater than 
that of genistein, and the recovery did not vary with soyfood 
or diet selection. Plasma concentration of isoflavones was 
2.7±1.3 |iinol/L 24 h after soymilk feeding. Plasma daidzein 
and genistein levels were approximately equal. Only a few 
percent of the total isoflavone dose was recovered in feces, 
probably due to bacterial breakdown of these compounds. 
Isoflavone bioavailability did not vary with the type of 
soyfood or background diet. 
Introduction 
Isoflavones are abundant in soy foods (0.2-1.5 mg/g) 
(Wang and Murphy 1994) with various amounts of isomers, three 
types (daidzein, genistein and glycitein) in four chemical 
forms (aglycone, glucoside, acetylglucoside, and 
malonylglucosides) (Kudou et al. 1991). Although biological 
activity of glycitein was not known, two major types of soy 
isoflavones, daidzein and genistein are proposed 
anticarcinogenic agents (Messina and Barnes, 1991). 
Substantial dietary isoflavone intake has been linked to 
the population who showed much lower breast and prostatic 
cancer incidence and mortality (Adlercreutz et al. 1995). 
In a rat study, hepatic cumene hydroperoxidase, an antioxidant 
enzyme, activity was significantly increased by feeding a diet 
containing soybean isoflavones extract (at 240 mg isoflavones 
/kg diet) for seven days (Hendrich et al. 1994) . Although 
mechanism of antiestrogenic activity of isoflavones has not 
been entirely clear yet, they can compete with estradiol for 
the nuclear type II binding sites (Adlercreutz et al. 1992), 
and inhibit human aromatase (an estrogen synthase) 
(Adlercreutz et al. 1993). P.ats consiiming a soy-based diet 
develop fewer mammary tumors following administration of the 
carcinogens N-methylnitrosourea and 7,12-dimethylbenz[a]-
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anthracene than rats on isonitrogenous and isocaloric diets 
without soy (Barnes et al. 1990). 
Isoflavones also demonstrated abilities to suppress tumor 
cell growth in vitro. Genistein inhibits the growth of 
estrogen receptor-negative or -positive human breast cancer 
cell lines {IC5o=24-44 ^mol/L; Peterson and Barnes 1991) . 
Daidzein and genistein (ICso of 8 |imol/L and 2.2 |imol/L, 
respectively) can inhibit production of inositol phosphates, 
key intracellular signals of proliferation stimulated by A1F4 
in 3T3 cells (Higashi and Ogawara 1992). Genistein also 
inhibits activation of tyrosine kinases which are a major 
class of oncogene products (IC5o=2.6 |lmol/L, Akiyama et al. 
1987), and topoisomerase II of human leukemic MOLT-4 and HL-60 
cells (IC5o=31.5 and 48 |lmol/L, respectively) but not the 
normal proliferating lymphocytes (Traganos et al. 1992). 
These findings suggest that isoflavones in soybean foods 
might play an important role in human health maintenance. 
Previous human feeding studies showed that absorption of 
isoflavones from soy milk with controlled liquid diet was dose 
dependent (Xu et al. 1994 and 1995) . However, in the real 
life situation people eat a variety of soy foods with 
different diet selections. These variations may affect soy 
isoflavone absorption and disposition among individuals. 
Since current clinical trial is hard to afford pure isoflavone 
standards and entirely controlled diet, investigating the 
effect of diet selections and type of soybean foods upon human 
isoflavone absorption and excretion are the purpose of 
following two studies. 
Subjects and methods 
Subjects and Protocol 
The procedures for this feeding study v;ere approved by 
the Human Subjects Committee of ISU. Informed consent of 
subjects was obtained in writing. All the subjects were 
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omnivorous, and in good health, based on medical histories and 
physical examinations performed by Student Health Center 
physicians at Iowa State University (ISU). Subjects did not 
take any medication such as antibiotics during entire feeding 
studies. 
Experiment One 
The subjects were eight adult women between 20 and 41 
years of age, with body weight of 58.35±10.49 kg and body mass 
index of 21.43±2.15 kg/m^ (Table 1). 
The study consisted of three feeding days, each separated 
by a one-week washout period (Table 1). On each feeding day. 
all subjects were fed three doses of isoflavones (0.9 mg/kg 
body weight in each meal) from soymilk powder (Now Foods, 
Inc., Glendale Hts.,IL) reconstituted with distilled water. 
The three doses of soymilk were served at 7:30 am, 12:30 am 
and 5:30 pm. 
A basic food diet (Table 2) was provided and consumed at 
7:30 am, 12:30 am and 5:30 pm, with the soymilk doses. When 
the subjects ate a self-selected diet, they chose their own 
foods but consumed at the same time as the soymilk doses. When 
the subjects ate ad libitum, they chose their own foods and 
consumed them at non-controlled times, but soymilk was 
consumed at the same times as with the other feeding regimens. 
Subjects consuming self-selected and ad libitum diets recorded 
their daily food intakes which were then analyzed by 
Nutritionist IV version 2.0 (N-SQUARED COMPUTING, Salem, OR). 
The subjects were also instructed not to eat any soybean foods 
or foods containing texturized vegetable protein, hydrolyzed 
vegetable protein, and soy protein isolate. A list of such 
foods was provided. Subjects were asked not to consume 
anything for 10 h before dosing. Subjects eating the basic 
food diet were instructed not to eat anything other than what 
was given on the feeding day. 
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Escperiment Two 
The subjects were ten young adult female between 20 and 
3 5 years of age, with body weight of 59.58±5.97 kg and body 
mass index of 21.60±1.25 kg/m^ (Table 3). Subjects were fed 
four types of soybean foods: tofu, texturized vegetable 
protein (TVP), tempeh, or cooked soybeans. Soyfood was given 
in the breakfast of each feeding day with a controlled diet 
(Table 4) for one day. The controlled diet was designed to 
meet subjects' average energy requirement based on their ages, 
body weights, and physical activity levels according to the 
Recommended Dietary Allowances tables (Food and Nutrition 
Board, National Research Council, 1989). Feeding days were 
separated by one-week washout periods (Table 3). Isoflavone 
dose ranged from 0.8-1.4 mg/kg body weight based on HPLC 
analysis of the soybean foods ingested. Subjects were 
instructed not to eat anything other than what was given on 
the feeding day. 
In both studies, subjects were asked not to eat any foods 
from a list of items which may contain isoflavones during the 
washout periods. No adverse effects such as diarrhea were 
reported after soy food dosing. 
Biological Sample Collection 
Blood samples. In both experiments, five mL venous blood 
samples were collected in heparinized vacuum containers by 
medical technologists under stringent aseptic condition at the 
Student Health Center, ISU. A blood sample was collected 
within one h before dosing (Time "0"). Blood samples were also 
collected at 6.5 and 24 h after dosing. Samples were 
centrifuged within one h after collection at 3000 x g for 20 
minutes at 4°C (Model 4D; International Equipment Co., Needham 
Hts., MA), and plasma was stored in a -20°C freezer. 
Urine samples. In Experiment One, for each subject, a urine 
sample was collected in the morning, before dosing (Time "0"). 
All urine was collected and pooled in four 12 h increments 
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over the first 48 h after dosing. The first urination of the 
third day after dosing was also collected. In Experiment Two, 
a urine sample was collected in the morning, before dosing 
(Time "0"). All urine in 24 h and first urination of the 
second day after dosing were collected. Urine samples were 
pooled during the following time intervals: Time "0", 0-12 h, 
12-24 h, and >24 h. After recording the total volume, 50 mL of 
each of the six samples was stored in a -20°C freezer. 
Fecal samples. In both experiments, capsules containing 1 g 
carmine red (Pharmaceutical Service, University of Iowa, Iowa 
City, lA) were given with the soymilk or soyfoods in the 
morning. One fecal sample from each subject was collected 
before soymilk feeding (Time "0"). After dosing, all feces 
excreted before and during fecal marker excretion were 
collected. Usually, the fecal marker appeared in feces one or 
two days after dosing. Fecal sample collection was stopped 
when the fecal marker no longer appeared in feces. After 
collecting the fecal samples, feces were freeze dried. After 
recording all the weights of dry samples, feces were ground to 
a fine powder in a coffee mill (Braun Company Inc., Lynnfield, 
MA). Ten g of each dry fecal sample was stored in a -20°C 
freezer until analysis. 
Soy Milk Powder and Soy Foods Analysis 
The concentrations of total isoflavones in soymilk powder 
and four soy food were measured as free isoflavones after 
hydrolysis in 1 mol/L HCl at 98°C following the method of Wang 
et al. (1990) . The method of HPLC analysis was as described by 
Wang and Murphy (1994). 
Biological Sample Analysis 
Plasma and urine samples. Sample preparation for plasma and 
urine isoflavone analysis was performed according to the 
methods described by Lundh et al. (1988). Plasma and urine 
samples were treated with glucuronidase/sulfatase (Sigma 
Chemicals Company, St. Louis, MO) to produce the parent 
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isoflavones. Chromatographic analysis followed the conditions 
described by Xu et al. (1994). Samples were automatically 
injected with a Spectra-Physics Autosampler Model 8780XR 
(Spectra-Physics, Fremont, CA). Isoflavones were separated in 
a Waters 3.9 mm i.d. x 30 cm length |l-Bondapak Ci8 reverse 
phase column with gradient elution at ambient temperature. Two 
Beckman Model llOB pumps,and one Beckman Model 420 
Microprocessor solvent flow controller were used. Beckman 
Model 163 variable wavelength detector set at 254 nm was 
connected with Beckman Model 427 Integrator by which 
chromatographic data were calculated and plotted. 
Daidzein (4',7-dihydroxyisoflavone) was obtained from 
Life Science Group, ICN Pharmaceuticals, Inc., Plainview, NY. 
Genistein (4',5,7-trihydroxyisoflavone) was obtained from 
Calbiochem Corporation, La Jolla, CA. Equol (4',7-
dihydroxyisoflavondiol) was a generous gift from Dr. H. 
Adlercreutz (Department of Clinical Chemistry, University of 
Helsinki, Finland). 
A series of standards of 0.25, 0.5, 1, 2, 3, 4, 6 |lg/mL, 
were run to quantify isoflavones. For each subject, plasma and 
urine samples were spiked randomly with daidzein, genistein 
and equol standards (100 |IL 1.5 |J.g/mL isoflavone added to each 
sample) to measure recovery. 
Fecal samples. Sample preparation and analysis were 
performed as described by Xu et al. (1994) . To ensure the 
quality of analysis, a series of standards (0.25, 0.5, 1, 2, 
3, 4, 6 |lg/mL) and fecal samples spiked with 500 |J,L of 8 |J,g/mL 
daidzein, genistein and equol standards were run to measure 
recovery. 
Statistical Methods 
Analysis of variance (General Linear Model) was used. 
Subjects and feeding times were treated as blocks. Effects of 
diet selection, time and type of isoflavones and soy foods as 
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well as subject and feeding time upon plasma concentration and 
urinary and fecal excretion were determined. Unweighted means 
were used for analysis of variance in Experiment Two (Snedecor 
and Cochran 1989). If the effect from any one of these factors 
other than type of isoflavones was significant, Tukey's test 
was used for comparison of means within the factor. The 
statistical analysis was performed with the Statistical 
Analysis System (SAS Institute, Inc., Gary, NC) version 6.06 
on the Iowa State University mainframe computer. A p value of 
0.05 or less was considered to be significant. 
Results 
Isoflavone concentration in soymilk powder was 1.25±0.08 
mg/g, daidzein and genistein were 44.0% and 56.0% 
respectively. Isoflavone concentrations of tofu, tempeh, 
texturized vegetable protein and cooked soybean were 0.42-0.58 
mg/g, 39.7-46.4% daidzein and 53.6-60.3% genistein (Table 5). 
Experiment One 
Average intakes of energy, carbohydrate and fiber were 
not significantly different among the three background diet, 
but the average intakes of fat, protein, and cholesterol from 
self-selected and ad libitum diets were significantly greater 
than those on the basic food diet (p<0.05) (Table 6). After 
consuming basic, self-selected, and ad libitum diets, 48 h 
urinary recovery of daidzein was 27±8%, 26±10% and 26+9%, 
respectively, and of genistein, 20±7%, 18±9%, and 18±8%, 
respectively (Table 7). Urinary recovery of daidzein was 
greater than that of genistein (p<0.05). Total fecal excretion 
of isoflavones was 4% of the ingested amount. No equol was 
found in any sample although the recovery of equol was between 
62-74% in all spiked samples. 
The amount of urinary isoflavones under all dietary 
conditions was about three times greater in the first 24 h 
after dosing than in the second 24 h after dosing (p<0.05) 
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(Table 8). After 48 h, urinary excretion of isoflavones was 
nearly nil. The amount excreted at each time point was similar 
among the three dietary conditions. The amount of urinary 
daidzein was twice that of genistein during the first 24 h 
after dosing (p<0.01). 
Variation in isoflavone content of biological samples was 
great among the subjects, especially for fecal samples. 
Subject Three excreted ten times more fecal isoflavones than 
the other subjects under all three dietary conditions. 
Plasma isoflavone concentration was significantly 
increased to an average of 1.3±0.5 |j,g/mL at 6.5 h after dosing 
compared with Time "0" (Table 9). The plasma concentrations of 
daidzein and genistein were not significantly different at 
this time. 
Experiment Two 
Amounts of total fat, fiber, and carbohydrate intake were 
not significantly different, but the amount of protein intake 
when subjects consiimed texturized vegetable protein was 
significantly greater than from the other three soy foods 
(Table 10). During feeding of the four soybean foods, 21-34% 
of the ingested total isoflavone dose was excreted (Table 11). 
Urinary recoveries of daidzein collected over 24 h after soy 
dosing from cooked soybean, texturized vegetable protein, 
tofu, and tempeh were 46±16%, 51±10%, 50±10%, and 38±18%, 
respectively, and of genistein, 13±6%, 14±8%, 16±5%, and 9±4%, 
respectively. Regardless of type of soy food, urinary 
recovery of daidzein was, on the average, 2.5 times greater 
than that of genistein (p<0.01). No significant variation of 
urinary recovery of isoflavones were observed among the 
soyfoods (p>0.1). Total fecal excretion of isoflavones was 2% 
of the ingested amount. Types of soybean foods and variation 
of dosages did not significantly alter plasma concentration of 
isoflavones (p>0.1) (Table 12). 
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Discussion 
On the average, cooked soybean, texturized vegetable 
protein, and soy milk powder contain more than 95% of total 
isoflavones as glycosides, whereas, tofu has about 20% of its 
isoflavones as aglycones, and tempeh has almost 40% of its 
isoflavones as aglycones (Wang and Murphy 1994). Glycosides 
of isoflavones are very poorly hydrolysed by mammalian 
intestinal digestive enzymes. Isoflavone glycosides are not 
favorable for absorption in the small intestine compared with 
their aglycones because of the higher hydrophilicity and 
greater molecular weight of the glycosides (Brown 1988). 
Average amounts of urinary isoflavones in both studies were 
20-3 5% of ingested doses (Tables 7, 11), which were much 
greater than the amount of isoflavone aglycones in cooked 
soybean and TVP, and did not vary with the varying content of 
aglycones among soy foods. This supports gut microfloral 
hydrolysis of glycosides to their isoflavone aglycones. 
Human intestinal bacteria especially, Lactobacilli, 
Bacteroides and Bifidobacteria, possess p-glucosidase activity 
(Hawksworth et al. 1971) . They may play a major role in 
liberating isoflavone aglycones and promoting isoflavone 
absorption. From proximal to distal small intestine, the 
amount of bacteria is increased from very low bacterial 
niombers in the upper 1/3 of small intestine to almost "colon­
like" resident flora in the lower 1/3 of small intestine 
(Heneghan 1988). Contents of both distal small intestine and 
large intestine in humans have substantial amount of 
Lactobacilli, Bacteroides and Bifidobacteria, and the number 
of each of three bacterium groups is about IC'-IO' bacteria per 
gram wet weight (Gorbach et al. 1967 and Mitsuoka 1982), 
whereas, contents of the human proximal small intestine 
contain almost none of these bacteria (Mitsuoka 1982). In 
addition, some bacteria in human large intestine also have p-
glucuronidase and arylsulfatase which can liberate aglycones 
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from conjugates derived from tissue phase II biotransformation 
(Sipes and Gandolfi 1991). This may facilitate reabsorption of 
isoflavones. 
Furthermore, the average length of time during which 
material stays in the intestine is about 5 min in the 
duodenum, 2 h in the jejunum, 3-6 h in the ileum, and 24 h or 
longer in the large intestine (Welling 1986) . Bacteria in 
distal small intestine and colon have much longer time to 
interact with isoflavones and perform their hydrolysis 
activities. 
In healthy human volunteers dietary fat absorption is 
practically completed in proximal small intestine after a meal 
containing 75 g of fat (Linscheer and Vergroesen 1988) . Fat 
might facilitate the absorption of isoflavone aglycones in 
proximal small intestine. However, free forms of isoflavone 
from soy milk powder were only 2-5% of ingested doses. 
Therefore, it is very unlikely that more than 95% of soy milk 
isoflavones will be absorbed along with dietary fat. In 
another study, seven healthy women were randomly assigned to 
low or high fat diet (20% or 40% of Kcalories from fat, 
respectively) containing a single dose of 0.9 mg isoflavones/ 
kg body wt from tofu or texturized vegetable protein for one 
day. Bioavailability of isoflavones as reflected on their 24 h 
urinary recoveries was not affect by the level of dietary fat 
intake (Tew et al., submitted). In this study, although the 
amount of fat intake from self-selected or ad libitum diet was 
3 0%-50% greater than that from the controlled basic foods 
diet, it did not alter isoflavone bioavailability among the 
three diets. 
Fat might affect bioavailability of isoflavones in 
relatively long-term feeding studies. After rats were fed a 
diet containing 12% corn oil for 4 weeks, the activity of 
phenol uridine diphosphate-glucuronyltransferase, a key enzyme 
for isoflavone biotransformation was significantly enhanced 
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(Nanbo et al. 1993). This can further alter isoflavone 
disposition in humans. In addition, dietary fat and protein 
might influence bioavailability of isoflavones through their 
effect on gut microflora. In a rat study, (J-glucosidase and p-
glucuronidase activities of caecal bacteria were increased 
with increasing dietary protein intake from 0% to 40% of diet 
for 10 days (Wise et al. 1983). Rats fed a diet containing 3 5% 
beef fat or olive oil in purified diet for 3 0 days can 
significantly decrease their total caecum bacterial P-
glucosidase activity and increase total caecum bacteria P-
glucuronidase activity by two fold in comparison to low fat 
diet containing 1% of safflower oil (Mallett et al. 1984). It 
is very possible that dietary fat and protein intake might 
also affect these enzyme activities of human gut bacteria. 
Since these bacterial enzymes are also important for 
isoflavone absorption and reabsorption, dietary effect on 
isoflavone bioavailability may be expected. In our study, 
differences in dietary protein and fat intake among three 
regimens had no effect upon isoflavone bioavailability after 
only one day feeding. 
Dietary insoluble fiber can bind to estrogens, 
especially, their aglycones in vitro (Whitten and Shultz 
1988). Because of structural similarity of isoflavones and 
estrogens, dietary water-insoluble fiber may also bind to free 
form isoflavones in intestine and decrease their absorption. 
Furthermore, dietary insoluble fiber can hold water and cause 
bulking effect of intestinal content in low bowel (Adlercreutz 
1984). This may reduce bacterium enzyme activities such as p-
glucosidase and P-glucuronidase, withine the same volume by 
dilution and prevent isoflavones from absorption and 
reabsorption. In another study conduct by our laboratory, 
seven healthy female human subjects were randomly assigned in 
a crossover design to a control diet or a wheat fiber 
supplemented diet (contain 15 g and 40 g of dietary fiber. 
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respectively). Each diet contained a single dose of 0.9 mg 
isoflavones/kg body wt from tofu or texturized vegetable 
protein. At 24 h after soy dosing plasma concentration of 
genistein in fiber rich diet groups was two fold lower than 
that in control diet. In addition, total 24 h urinary 
genistein in wheat fiber supplemented diet was 20% lower than 
that in control diet (Tew et al. b, in press). In this study, 
dietary intake of insoluble fiber was not significantly 
different among three diet selections. This may be one of main 
reasons why there was no significant difference in 
bioavailability reflected on 48 h urinary recoveries of 
isoflavones. 
From experiment one, it was concluded that human 
absorption, excretion and plasma concentration of isoflavones 
do not depend upon diet selections with different amounts of 
fat and protein but similar amounts of dietary fiber. This 
suggests that in future studies, ad libitum diets may be 
appropriate in short-term isoflavone feeding studies in 
humans. 
Although the four soy foods studied contained various 
amounts of isoflavone glycosidic conjugates and aglycones, 
urinary recoveries of both daidzein and genistein were not 
significantly different among four soy food treatments (Table 
11). Almond p-glycosidases can hydrolyze the p-glycosidic 
bond between the carbohydrate moiety and the isoflavonoid 
nucleus regardless of the difference in carbohydrate group 
(Farmakalidis and Murphy 1985). If P-glucosidase of gut 
bacteria act similarly to almond (i-glycosidase, urinary 
recoveries of daidzein and genistein may not be affected by 
differences in isoflavone glycoside forms in soybean and soy 
foods. Our data do support this concept. 
Four soybean foods provided similar hiiman 
bioavailability. Average isoflavone urinary recovery of 
daidzein was about 10 - 15 % higher than that of soymilk. 
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These certainly suggested that common soybean foods might 
provide more daidzein than genistein and further investigation 
of biological activity of daidzein might be important. 
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Table 1. Experiment 1: Design^ 
Subj ect Feeding 1 Washout — Feeding 2 Washout > Feeding 3 
(1 day) (1 week) (1 day) (1 week) (1 day) 
Body Dietary Dietary Dietary 
No. , Age Weight mass index Assignment Assignment Assignment 
(kg) (kg/m2) 
1 20 59, .1 20 .45 BF AL SS 
2 21 60, .0 20 . 14 SS BF AL 
3 41 84, .4 26 . 90 BF SS AL 
4 29 51, .1 21 .71 BF AL SS 
5 22 54, .4 20 . 08 SS AL BF 
6 21 52 . 2 19 . 93 AL BF SS 
7 20 56. .7 21 .49 AL SS BF 
8 23 48 . 9 20 .76 SS BF AL 
X 24 58. ,35 21 .43 
SD 6.4 10. , 49 2 . 15 
^All subjects were fed 0.9 mg isoflavones/kg body wt in three meals for one day. 
BF = timed basic foods diet, SS = timed self-selected foods diet, AL = Ad Libitum 
diet. 
Table 2. Basic foods diet 
Food Approximate time 
Toasted plain bagel 7:30 AM 
Grape jam 7:30 AM 
Unsweetened orange juice 7:30 AM 
Soybean milk 




Apple 12:30 AM 
Pringles's chip (regular) 12:30 AM 
Water 12:30 AM 
Sandwich 5:30 PM 
White bread 
Colby Jack cheese 
Mustard 
Tostitos tortilla chips 5:30 PM 
(regular) 






1 medium (3" diameter) 
1 Tbsp. (0.7 oz.) 
1 Cup (8 f1. oz.) 
2 slices (3.6 oz.) 
1 oz. 
1 medium (4.9 oz.) 
15 (1.05 oz.) 
250 ml 
2 slices (3.6 oz.) 
1 oz. 
15 (0.9 oz.) 
1 Cup (8 f1. oz.) 
22 (1 oz.) 
1 medium (4.9 oz.) 
Table 3. Experiment 2: Design^" 
Subject Feeding 1 Feeding 2 Feeding 3 Feeding 4 
(1 day) (1 day) (1 day) (1 day) 
Body Soy Food Soy Food Soy Food Soy Food 
No. Age Weight Mass index 
(kg) (kg/m2) 
1 20 59 . 1 20, .45 CS TVP TF TP 
2 24 50 . 9 20, .13 CS • TVP TP 
3 27 61. 4 21, .46 * TVP CS TP 
4 32 70 . 9 24, ,31 • -k CS TVP 
5 20 55 . 9 21, .32 • •k CS TVP 
6 23 50 . 9 19, ,87 TVP CS TP TF 
7 25 55 . 9 22, .10 TVP CS TP TF 
8 32 63 . 6 22, . 12 Vk- * TVP CS 
9 35 63 . 6 21. 56 * TVP TF CS 













^CS= cooked soybean, TVP= texturized vegetable protein, TF= tofu, TP= tempeh. 
Data of subject with * was not used because consumed soybean foods were not available 
for isoflavone analysis. 
^There was one week washout period between feedings. 
Table 4. Controlled diet of Experiment 2 
Food Approximate 
Breakfast casserole 7:30 AM 
Soy foods 
1 large egg 
Kraft sharp cheddar cheese 
Pace thick & chunky salsa 
White sandwich bread 
Tropicana unsweetened orange juice 
distilled water 









Colby Jack cheese 
Mustard 
Tostitos tortilla chips (regular) 












8 f1. oz. 
250 ml 
2 slices (3.6 oz.) 
1 oz. 
1 medium (4.9 oz.) 
20 (40 g) 
250 ml 
2 slices (3.6 oz.) 
1 oz. 
17 (45 g) 
8 f1. oz. 
40 g 
1 medium (4.9 oz.) 
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Table 5. Soy Food Analysis 
Soy Foods Isoflavone & of % of 
Concentration Daidzein Genistein 
(mg/g) 
Soy milk powder 1, .25±0. 08 44. 0 56. , 0 
Tofu 0 , .46±0. 09 42 . 6 57 , .4 
Tempeh 0, .64±0. 02 39 , .7 60 , .3 
Texturized 0 .42±0. 01 46, .4 53 , .6 
Vegetable Protein 
Cooked Soybean 0 .58+0, .02 46 .4 53 .6 
Table 6. Nutritional Analysis of Basic Food Diet, Self-Selected Diet 
and Ad Lib Diet^ ^ 
Basic Food Self-Selected Ad Lib 
{n=i 3) (n=8) (n= = 8) 
Kilocalories 1895 + 18. 97 1986 ± 34 . 67 2212 ± 32.14 
Protein (g) 58.2 + 3 .12^ 81.34 ± 6. CD tr
 
84.95 + 7.91'' 
Carbohydrate(g) 326.1 ± 2.28 294.5 ± 7 . 10 347 .3 + 5.89 
Total Fat (g) 44.06 ± 1. 63^ 56.93 ± 5. 26*^  62.99 ± 6.31^^ 
Cholesterol(mg) 54.00 + 0.00^ 127.4 ± 7. 43b 118.4 + 5.82'^  
Saturated Fat(g) 15.17 + 0.28^ 23.58 ± 1. se'' 25.36 + 1.90'^  
Monounsaurated Fat(g) 22.81 ± 0.63^ 26.89 ± 3. 17b 30. 67 ± 2.69" 
Soluble Fiber(g) 2.47 + 0.06 2.70 ± 0 . 68 2 .47 ± 0.77 
Insoluble Fiber(g) 9.20 ± 0.26 10.15 ± 2 . 87 9.69 ± 1.18 
^Means and SD are presented in the table. Values bearing different letters in a row 
are significantly different (p<0.05). ANOVA were used for comparison of means. A p 
value of 0.05 or less was considered to be significant. 
^Nutritional analysis was performed with Nutritionist IV version 2.0 ( N-SQUARED 
COMPUTING, Salem, OR). 
Table 7. Isoflavone excretion under three diet selection^ 
Diet selection 
Isoflavones 
Basic foods Self-selected Ad lid foods 
foods 
Intake 
Daidzein(mg) 88, .23 + 15 . 87 88 .23 + 15 . 87 88 .23 ± 15 . 87 
Genistein(mg) 69, .31 + 12 . 47 69 .31 + 12 .47 69 .31 + 12 .47 
Total intake(mg) 157 , . 54 + 28 .34 157 .54 + 28 . 34 157 . 54 ± 28 .34 
Urinary excretion(mg)^ 38. 80 + 11. 72 35 . 30 + 10. 43 35. 38 ± 9. 17 
Daidzein recovery (%)^ 27 .25 + 7 . 58 25. 68 + 10. 84 26. 30 + 8 . 63 
Genistein recovery (%) 20. 41 + 10, .18 00
 
23 : t 9. 38 17 . 57 : ± 8.40 
Fecal excretion (mg) 4 . 37 ± 3 . 95 4. 48 + 3 . 12 3 . 96 + 3 . 08 
% Isoflavone excreted 
in urine and feces 27 , ,40 + 9, .64 25 .25 + 9 .45 24 . 97 ± 8 .72 
•^Values are means and standard deviations; n=8; mg/kg = mg of isoflavones per kg 
body weight. BF = basic foods, SS = self-select foods, AL = Ad Lib foods. 
^Urine samples included all the urine in the first 24 hours after dosing and the 
first urination of the second day. 
^The urinary recovery of daidzein was significantly greater than that of 
genistein in each diet selection (p<0.05). 
^Fecal samples included all feces excreted before and during fecal marker 
excretion. 
Table 8. Urinary excretion of isoflavones under three diet selection^ 
Isoflavone Time "0" 0-12 Hours 12-24 Hours 24-36 Hours 36-48 Hours >48 Hours 
mg 
Basic foods 
Daidzein 0, .02±0. ,02 10 .24±3 . 00 10, .13± 7 . 06 2. 41±1. 28 0 . 91±0, .89 0, .1810 .34 
Genistein ND 5 .02±2, .32 5, .56± 4 .75 1. 99+2. 09 1, .12 + 1. 76 0. 34+0, .46 
Total 0. 02+0. 02 15, .26+5, .32 15. .69±11, .81 4. 40±3 . 37 2 , .03+2. .65 0. 5210, .80 
Self-selected foods 
Daidzein 0. 14+0. 26 9, .47±1, .88 9. .47± 4, .25 2 .77±3 . 55 0, .66±0. 78 0. 0910, .11 
Genistein 0. ,02±0. 06 3 . 69±1. 43 4. .61+ 3 . 17 3 .19 + 5 . 01 0. 98±1, ,95 0. , 1410. 30 
Total 0. ,16±0. ,32 13 . ,16±3. 31 14 . 08± 7 . 42 5 .96±8 . 56 1. 64±2. 73 0. ,23+0. 41 
Ad lid foods 
Daidzein 0. 02±0. 05 9. 77+3. ,17 9. , 71± 4, ,29 2 .53+2 . 04 1. ,04±0. 92 0. 12 + 0. , 13 
Genistein 0. ,03±0. 07 4. 21±2. , 62 4. ,22± 5. 44 2 .4512 .86 1. ,13±1. , 59 0. ,1410. ,21 
Total 0. ,05±0. 12 13 . 98±5. ,79 13 . ,93± 9, ,73 4 . 98±4 .90 2 . ,17±2. 51 0. 2610. ,34 
^Values are means and standard deviations; mg/kg = mg of isoflavones per kg body 
weight; ND = Not detectable, at a detection limit of 2 ng per 20 |IL injected. 
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Table 9. Plasma concentration of isoflavones under three 
diet selection^ 






































^Values are means and standard deviations; n=8; mg/kg = mg 
of isoflavones per kg body weight; ND = Not detectable, at a 
detection limit of 2 ng per 20 |IL injected. Subjects were 
given 0.9 mg/kg body weight isoflavones in three meals. 
Table 10. Nutritional Analysis of soybean foods Diet^^ 
Cooked soybean Texturized Tofu Tempeh 
vegetable protein 
(n=10) {n=10) (n=5) (n=4) 
Kilocalories 2156.86 ± 20.49 2315.71 ± 76.82 2165.25 ± 10.27 2136.54 ±22.10 
Protein(g) 76.55 ± 2.02*^ 118.12 ± 14.57^ 78.58 ± 2.09*^ 74.90 ± 2.21'^ 
Carbohydrate(g) 296.91 ± 1.18 289.00 ± 0.00 292.90 ± 0.29 294.16 ± 0.98 
Total Fat(g) 80.72 + 1.07 74.69 + 0.21 76.40 ± 0.68 79.42 ± 1.12 
Cholesterol(mg) 307.00 ± 0.00 307.00 ± 0.00 307.00 ± 0.00 307.00 ± 0.00 
Saturated fat(g) 30.13 ± 0.15 29.10 ± 0.00 30.30 ± 0.10 29.10 ± 0.00 
Total fiber(g) 21.78 ± 0.52 20.77 ± 0.68 19.85 ± 0.08 20.52 ± 0.42 
^Means and SD are presented in the table. Values bearing different letters in a row 
are significantly different {p<0.05). ANOVA were used for comparison of means. A p 
value of 0.05 or less was considered to be significant. 
^Nutritional analysis was performed with Nutritionist IV version 2.0 ( N-SQUARED 
COMPUTING, Salem, OR) . 
Table 11. Isoflavone excretion after feeding soybean foods^ 
Soybean foods 
Cooked soybean Texturized Tofu Tempeh 
vegetable protein 
(n=10) (n=10) (n=5) (n=4) 
Intake 
Daidzein(mg) 20 .38 ± 1 .84 27 .75 ± 4. 16 36 .76 + 9 .43 21.77 ± 9.91 
Genistein(mg) 24 .02 ± 2 .41 32 . 05 ± 4. 34 42 . 82 ± 12 .47 29.57 ± 10.22 
Total intake(mg) 44 .40 + 3 .23 59 . 80 ± 8. 44 79 . 58 + 21 . 89 51.34 ± 20.12 
Urinary recovery (%) ^'^ 
Daidzein 45 .45 + 15 . 90® 50. 66 + 10 .17® 50. 12 + 10. 02® 37.99 ± 18.90® 
Genistein 12 .75 ± 6 .30'^ 13 . 45 + 7 .66'^ 16. 07 ± 5. 33*= 8.51 ± 3.86'^ 
Fecal excretion (mg) •* 1. 02 ± 0. 66 1. 11 + 0. 32 1. 09 + 0. 24 1.20 ± 0.23 
% Isoflavone excreted 
in urine and feces 30 .27 ± 11.54 32 .75 + 8. 89 34 . 01 + 6 .72 21.31 ±9.83 
Values are means and standard deviations. 
^Urine samples included all the urine in the first 24 h after dosing and the first 
urination of the second day. 
^Values bearing different letters in column are significantly different from each 
other (p<0.01). 
^Fecal samples included all feces excreted before and during fecal marker 
excretion. 
Table 12. Plasma concentration of isoflavones after feeding soybean foods^ 
Soy foods Isoflavone Dosage Time "0" 6.5 Hours 24 Hours 
(mg/kg) 
|J.g/ml 
Cooked Daidzein 0 .35 + 0, .03 ND 0, .25 ± 0, .09 0, .03 ± 0, .00 
soybean Genistein 0 .40 ± 0, .02 ND 0 .29 + 0, .09 0. 03 ± 0, .01 
(n=10) Total 0, .75 + 0. ,04 ND 0, .55 + 0. ,18 0. ,06 ± 0, .01 
Texturized Daidzein 0, ,46 ± 0. ,03 ND 0. 35 + 0. ,12 0. ,04 ± 0, .02 
vegetable Genistein 0. .54 ± 0. ,03 ND 0. ,27 + 0. ,06 0. ,06 ± 0, .07 
protein Total 1. .00 + 0, ,05 ND 0. .62 ± 0, , 17 0, , 10 ± 0, , 09 
(n=10) 
Tofu Daidzein 0. ,63 + 0. ,12 ND 0. ,38 + 0. 15 0. 04 ± 0. , 01 
(n=4) Genistein 0. , 81 + 0 . ,17 ND 0. ,37 + 0. , 10 0. ,04 ± 0. , 02 
Total 1. ,44 + 0. ,21 ND 0. ,75 + 0. 25 0. 08 ± 0. , 03 
Tempeh Daidzein 0. ,39 + 0. , 15 ND 0. ,28 + 0. ,07 0. 04 ± 0. , 01 
(n=5) Genistein 0. ,53 ± 0. , 14 ND 0, ,28 ± 0. 06 0. 04 + 0. 03 
Total 0 , , 92 + 0, ,18 ND 0. , 56 + 0. 12 0. 08 ± 0. 04 
^Values are means and standard deviations; mg/kg = mg of isoflavones per kg body 
weight; ND = Not detectable, at a detection limit of 2 ng per 20 |iL injected. 
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IV. HUMAN ISOFLAVONE BIOAVAILABILITY AND NATURAL KILLER 
CELL ACTIVITY AFTER SEVEN DAY SOYMILK FEEDING ^ 
A paper to be submitted to the Journal of Nutrition 
Xia Xu, Shavonta Dickerson, Joan E. Cunnick, 
Patricia A. Murphy, and Suzanne Hendrich^ 
Abstract 
To characterize the relationship between 
bioavailability of soybean isoflavones and a short-term 
indicator of their potential health protective effects in 
humans, eight women and eight men, ages 20-28, were fed 0, 0.8 
or 1.6 mg isoflavones/kg body wt from soymilk in breakfast for 
seven days in a randomized cross-over design. Each subject 
consumed an ad libitum diet with the soymilk. There was a 
one-week washout period between soymilk doses. In each 
feeding week plasma samples were taken in the morning before 
the first soymilk dose, and 6.5 h after the last soymilk 
ingestion. Twenty-four h urine collections were conducted on 
the last two days of each feeding period. Fecal samples were 
collected over the last two days of each feeding week until 
fecal marker no longer appeared in feces. Plasma, urine and 
fecal isoflavones were measured by reverse-phase HPLC. 
Peripheral blood natural killer cell activities were also 
measured. Plasma concentrations of isoflavones were dose-
dependent after soymilk feeding, however, blood natural killer 
cell activities were not affected by increasing of soy doses 
and plasma isoflavone concentrations (p>0.1). Plasma 
^ Supported by Iowa Soybean Promotion Board, Center for 
Designing Foods to Improve Nutrition, Iowa State University, 
Ames, lA 50011, Journal paper No. J- , Iowa Agriculture and 
Home Economics Experiment Station, Project No. 3075. 
^ Author for correspondence. 
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daidzein concentration in males was significantly greater than 
that in females after soymilk dosing (p<0.01). In all 
subjects, urinary excretion of isoflavones was nearly the same 
on day 6 and 7. Urinary daidzein was about two-fold greater 
than genistein, 10-13 times greater than equol on both feeding 
days. These data suggest that human disposition of daidzein 
after an oral dose differs between males and females, however, 
daidzein, genistein and equol seem to be at steady state by 
six days of feeding in our human subjects. The effect of 
isoflavones upon natural killer cell activities need to be 
further investigated. 
Introduction 
Isoflavones, daidzin, genistin and their aglycones, 
daidzein and genistein are abundant in soy foods (0.2-1.5 
mg/g) (Wang and Murphy 1994) . Substantial soybean isoflavones 
intake has been implicated as one of the important factors 
responsible for lower incidence and mortality of breast, 
prostatic and colorectal cancers in eastern Asia (Adlercreutz 
et al., 1995). Mechanism of isoflavone health protective 
effects are the topic of much current research. Isoflavones 
are antioxidants and can enhance activities of antioxidant 
enzymes in vivo (Hendrich et al., 1994) and in vitro (Wei et 
al., 1995). They are weakly estrogenic and also 
antiestrogenic (Adlercreutz et al. , 1991). Genistein and 
daidzein have demonstrated many anticarcinogenic activities in 
vitro (Barnes 1995, Fotsis et al. 1993, and Higashi and 
Ogawara 1992). 
In addition to direct tumor inhibitory effect, flavonoids 
may perform health protective function through their ability 
to enhance natural killer activity (Wiltrout and Hornung, 
1989). In a preliminary study, soy isoflavone extract was 
found to significantly increase the activity of liver 
associated natural killer cells after feeding 240 mg 
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isoflavones/kg diet for 10 days (Cunnick and Hendrich, 
unpublished data). Natural killer activity plays an essential 
role in immune surveillance against tumor development and 
progression as well as infectious agents (Whiteside and 
Herberman, 1989). Isoflavones acting as antioxidants can 
enhance glutathione peroxidase activity (Hendrich et al., 
1994) which constrains prostaglandin production (Marshall et 
al., 1988). Prostaglandins from monocytes inhibit blood 
natural killer activity in breast cancer patients (Baxevanis 
et al., 1993). On the other hand, isoflavones, especially, 
genistein is a specific inhibitor of tyrosine kinase. Since 
tyrosine kinase activity is crucial for the activation of 
natural killer cell, it is reasonable to hypothesize that 
soybean isoflavones can either enhance or inhibit natural 
killer activity, and natural killer cell activity varies with 
plasma isoflavone concentrations. The present soy milk human 
feeding study was conducted to investigate these hypotheses. 
Our previous human studies demonstrate that 
bioavailability of soy isoflavones is dose dependent (Xu et 
al., 1994 and 1995). Subjects in those studies were only 
females and they received soy doses for no more than one day. 
In this study men and women received soy milk doses for seven 
days, and their isoflavone absorption and disposition pattern 
as well as their relationship with activities of natural 
killer cells were characterized. 
Materials and methods 
Subjects and Protocol. 
The procedures for this feeding study were approved by 
the Human Subjects Committee of ISU. Informed consent of 
subjects was obtained in writing. All the subjects were 
omnivorous, and in good health, based on medical histories and 
physical examinations performed by Student Health Center 
physicians at Iowa State University (ISU). Subjects did not 
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take any medication such as antibiotics during the entire 
feeding studies. 
The subjects were eight young adult women and eight young 
adult men between 20 and 28 years of age, with body weight of 
63.0 ± 6.3 kg and 7 9.0 ± 9.4 kg for females and males, 
respectively, and body mass index of 22.8 ± 2.1 kg/m^ and 22.6 
± 2.3 kg/m^ for females and males, respectively. 
The cross-over design experiment consisted of three 
seven-day feeding weeks, each separated by a one-week washout 
period. On each morning of the feeding week, every subject 
received 0, 0.8 or 1.6 mg isoflavones/kg body wt from soymilk 
powder (Now Foods, Inc., Glendale Hts.,IL) reconstituted with 
chocolate milk or 1% fat plain milk. Subjects ate an ad 
libitum diet during the study and recorded their food intake 
at last two days of each feeding. The subjects were also 
instructed not to eat any other soybean foods or foods 
containing texturized vegetable protein, hydrolyzed vegetable 
protein, and soy protein isolate during the entire study. A 
list of such foods was provided. Subjects were asked not to 
consume anything for 10 h before the first day of dosing. No 
adverse effects such as diarrhea were reported after soy food 
dosing. 
Blood, Urine and Fecal Sample Collections. 
Thirty mL venous blood samples were collected in 
heparinized vacuum containers by medical technologists under 
stringent aseptic condition. A blood sample was collected 
within one h before first dosing. Blood samples were also 
collected at 6.5 h after the last dosing. Ten ml of the 
sample was immediately processed for natural killer cell 
activity; another 10 ml sample was used for measurement of 
glutathione peroxidase activity and prostaglandin level (data 
not presented); the third 10 ml sample was centrifuged within 
one h after collection at 3000 x g for 20 minutes at 4°C 
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(Model 4D; International Equipment Co., Needham Hts., MA), and 
plasma was stored in a -20°C freezer. 
All urine was collected and pooled in four 12 h 
increments over the last two days of feeding. The first 
urination of the eighth day was also collected. After 
recording the total volume, 50 mL of each of the five samples 
was stored in a -20°C freezer. 
Capsules containing 1 g carmine red (Pharmaceutical 
Service, University of Iowa, Iowa City, lA) were given with 
the soymilk in the morning of last two days of feeding. All 
feces excreted before and during fecal marker excretion were 
collected. Fecal sample collection was stopped when the fecal 
marker no longer appeared in feces. After collecting the 
fecal samples, feces were freeze dried. After recording all 
the weights of dry samples, feces were ground to a fine powder 
in a coffee mill (Braun Company Inc., Lynnfield, MA). Ten g 
of each dry fecal sample was stored in a -20°C freezer until 
analysis. 
Soy Milk Pov/der and Soy Foods Analysis. 
The concentrations of twelve isoflavone isomers in 
soymilk powder were measured according to the method described 
by Wang and Murphy (1994). 
Plasma, Urine and Fecal Sample Analysis. 
Sample preparation for plasma and urine isoflavone 
analysis was performed according to the methods described by 
Lundh et al. (1988). Plasma and urine samples were treated 
with glucuronidase/sulfatase (Sigma Chemicals Company, St. 
Louis, MO) to produce the parent isoflavones. Chromatographic 
analysis followed the conditions described by Xu et al. 
(1994). Samples V7ere automatically injected V7ith a Spectra-
Physics Autosampler Model 8780XR (Spectra-Physics, Fremont, 
CA). Isoflavones were separated in a Waters 3.9 mm i.d. x 3 0 
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cm length |l-Bondapak Ci8 reverse phase column with gradient 
elution at ambient temperature. Two Beckman Model llOB 
pumps,and one Beckman Model 420 Microprocessor solvent flow 
controller were used. Beckman Model 163 variable wavelength 
detector set at 254 nm was connected with Beckman Model 427 
Integrator by which chromatographic data were calculated and 
plotted. 
Daidzein (4',7-dihydroxyisoflavone) was obtained from 
Life Science Group, ICN Pharmaceuticals, Inc., Plainview, NY. 
Genistein (4',5,7-trihydroxyisoflavone) was obtained from 
Calbiochem Corporation, La Jolla, CA. Equol (4',7-
dihydroxyisoflavondiol) was a generous gift from Dr. H. 
Adlercreutz (Department of Clinical Chemistry, University of 
Helsinki, Finland). 
A series of standards of 0.25, 0.5, 1, 2, 3, 4, 6 |Llg/mL, 
were run to quantify isoflavones. For each subject, plasma and 
urine samples were spiked randomly with daidzein, genistein 
and equol standards (0.15 |J,g isoflavone/lOO jlL added to each 
sample) to measure recovery. 
Fecal sample preparation and analysis were performed as 
described by Xu et al.(1994). To ensure the quality of 
analysis, a series of standards (0.25, 0.5, 1, 2, 3, 4, 5 
jig/mL) and fecal samples spiked with 500 |iL of 8 |Ig/mL 
daidzein, genistein and equol standards were run to measure 
recovery. 
Natural Killer Activity Assay 
The blood was diluted 1:1 with HESS (GIBCO) and 4 ml 
layered over 3 ml of Ficol-hypaque (Pharmacia), and 
centrifuged for 20 min at 400 g. The interface were washed 3 
times with HBSS, enumerated using the NOVA Cell-Track (NOVA 
Biochemical), and diluted to 10® cells/ml in complete media (2 
mM L-glutamine, 5 mM HEPES, 50 |lg/mL glutamine and 10 % FBS, 
BIBCO-BRL). The natural killer activity of isolated cell was 
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measured using a cell mediated cytotoxicity assay and ^^Cr-
release from labeled targets (Cunnick et al., 1988). The 
target cells (K562) were labeled for 70 min by incubating 7.5 
X 10® targets with 200 |LlCi of ^^Cr (as sterile aqueous sodium 
chromate, Dupont-NEN). The targets were washed 3 times to 
remove exogenous ^^Cr and incubated (37°C) for 30 min prior to 
the last wash to reduce spontaneous release during the assay. 
The effectors and targets were plated in triplicate at 4 
ratios of 50:1, 25:1, 12.5:1, and 6.25:1 in a total volume of 
250 |j.l in 96 well plates. Controls consisted of wells 
containing 250 |ll if media with targets alone (Spontaneous 
release) and wells containing 100 |_il of targets (For Maximum 
release). The cultures were incubated for 4.5 h at 3 7°C in a 
humidified COj (5%) incubator. 
At the end of the incubation period 150 |U,1 of 10% 
Trichloroacetic acid (TCA) was added to the maximum release 
control wells to lyse all targets. The plates were 
centrifuged for 5 min at 500 rpm, 100 |ll of the supernate were 
removed from each well. The radioactivity of the samples were 
determined on a gamma-scintillation counter (Gamma-Track) . 
Statistical Methods 
Analysis of variance (General Linear Model) were used. 
Subjects and feeding times were treated as blocks. Effects of 
gender, plasma concentration and type of isoflavones as well 
as subject and feeding time upon NK cell activity were 
determined. Linear regression model relating NK activity and 
effector to target ratio was estimated. Meanwhile, effects of 
gender, dosage and type of isoflavones as well as subject and 
feeding time upon plasma, urine and fecal isoflavone levels 
were also evaluated. If the effect from any one of these 
factors other than gender and type of isoflavones v/as 
significant, Tukey's test was used for comparison within the 
factor. The statistical analysis was performed with the 
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Statistical Analysis System (SAS Institute, Inc., Gary, NC) 
version 6.06 on the Iowa State University mainframe computer, 
A P value of 0.05 or less was considered to be significant. 
Results 
Men had greater amounts of total energy intake as well as 
protein, total fat, carbohydrate and insoluble fiber intake 
than those of women in each of last two days of feeding (Table 
1) . 
Isoflavone concentrations in soymilk powder were 
presented in Table 2. Plasma concentrations of isoflavones 
were dose-dependent after soymilk feeding (Table 3). Plasma 
daidzein concentration in males was significantly greater than 
that in females after soymilk dosing (P < 0.01). 
In both men and women blood natural killer cell 
activities after one week soy milk ingestion were not 
significantly affected by the isoflavone dosages, nor were 
plasma isoflavone concentrations (P > 0.1). Although average 
NK cell activities of male subjects were 20-25% greater than 
those of females after soy milk ingestion (Table 4), the 
difference between genders was not significant (P > 0.1) due 
to great overall variation among subjects. Natural killer 
cell activity of both genders at each dosage was decreased by 
the reducing of effector to target ratio in a approximate 
linear relationship (r^=0.78). 
Urinary excretion of isoflavones on day six of feeding 
was very close to that on day seven (Table 5). Male subjects 
excreted significantly greater amount of daidzein than female 
subjects did after soy milk dosing (P < 0.01). For both male 
and female subjects, urinary daidzein was about two fold 
greater than genistein in each of last two feeding days (P < 
0.01). Only a small amount of equol, about one tenth to one 
thirteenth of the amount of daidzein, was found in urine on 
each day. 
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The amounts of fecal isoflavone excretion were not 
affected by sex or type of isoflavones {P > 0.1) (Table 6) . 
Fecal isoflavone excretion was significantly increased with 
the isoflavone dosages (P < 0.05) . There were great 
variations among subjects. One woman excreted about 7-8 times 
more isoflavones than other women. Two men had about two to 
three fold greater fecal isoflavone excretion than did other 
men at 1.6 mg /kg body wt dosage. 
Discussion 
This study extends our knowledge of soy isoflavone 
absorption and excretion to continuous soy milk feeding rather 
than single dose. As reported in our previous studies (Xu et 
al., 1994 and 1995), daidzein had much greater bioavailability 
than genistein, and fecal excretion of soy isoflavones was 
very low in most of our subjects. These are still true in 
this study (Tables 3, 5 and 6). Furthermore, similar to 
pattern we saw in previous study (Xu et al., 1995), one female 
subject who excreted 7-8 times more fecal isoflavones did have 
greater over urinary excretion of isoflavones, especially, 
genistein compared to subjects with close body weight in the 
same study. 
At 6.5 h after seventh soy milk dosing in this study, 
average plasma concentrations of daidzein and genistein after 
0.8 mg/ kg dosage were about 1.93 and 1.73 |iM, respectively, 
and 2.96 and 2.71 |iM, respectively, after 1.6 mg/ kg dosage 
(Table 3) . Whereas, at 6.5 h after single soy milk dosing in 
previous study (Xu et al., 1994), average plasma 
concentrations of daidzein and genistein were 1.22 and 1.07 
IIM, respectively, after 1.3 mg/ kg dosage, and 2.24 and 2.15 
|iM, respectively, after 2.0 mg/ kg dosage. These differences 
suggested that continuous soy milk dosing in 24 h interval may 
still prolong and increase the presence of isoflavones in 
plasma compared to single soy milk dosing. This certainly 
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enhance the chance for isoflavones to exert their health 
protective effects through physiological amounts of soy food 
consumption. 
Urinary excretion of isoflavones at day 6 and day 7 of 
continuous soy milk feeding were very close at each of two 
isoflavone dosages (Table 5). This suggested that absorption 
and excretion of isoflavones may already enter a steady state 
after six days of continuous soy milk dosing. In addition, 
equol was found in plasma, urine and feces at day 6 and day 7 
of continuous soy milk feeding although it was only present in 
a small amount (Tables 3, 5 and 6). In previous single day 
soy milk feeding studies no equol was detected in plasma, 
urine and fecal samples (Xu et al., 1994 and 1995). This 
difference suggested that human subjects in our study may need 
several days of soy ingestion to achieve the induction of 
equol production by gut microflora. 
Sex-related differences have been reported in the 
activity of liver sulf©transferases, but not UDP-
glucuronosyltransferases, toward phenolic compounds in rats, 
with the activity of phenol sulfotransferase being two- to 
threefold higher in cytosol prepared from liver of adult male 
rats compared to females (Matsui and Watanabe, 1982; Singer et 
al. , 1982) . Consistent with these in vitro data, Meerman et 
al. (1987) reported that male rats excreted a significantly 
greater amount of phenol with higher percentage of them as 
phenolic sulfates and no difference in phenolic glucuronides 
compared to female rats following iv administration of 133 
jimol phenol/ kg body wt. In our study males excreted about 80 
% more isoflavones than females did on day 6 or 7 (Table 5). 
Plasma concentration of daidzein in male subjects was 
significantly greater than that of females (Table 3). This 
difference may be due to greater sulfotransferation of 
isoflavones in men, which promote their urinary isoflavone 
excretion, prohibit rapid distribution of absorbed isoflavones 
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into the tissues and maintain greater plasma concentration, 
especially, daidzein since daidzein is more hydrophilic than 
genistein. Study to compare urinary excretion of isoflavone 
sulfates and glucuronides between male and female subjects as 
well as sulfotransferation of daidzein and genistein will help 
to examine our hypothesis. 
Isoflavones can have a profound impact on natural killer 
cell activity. NK activity is regulated in a negative manner 
by prostaglandins (Herberman, 1989) which are produced by many 
cells of the body including macrophages and neutrophils 
(Kunkle et al., 1984). Of particular interest is PGEj which 
inhibits T-cell production of IL-2 as well as NK cell activity 
(Baxevanis et al. , 1993; Ohnishi et al., 1991). Several 
tumors have been shown to produce PGEj and are then able to 
down regulate the immune system and escape lysis (Earnest et 
al. , 1992) . Inhibitors of the cyclo-oxygenase pathway such as 
indomethacin are known to decrease PGEj synthesis (Earnest et 
al. , 1992) . This decrease in PGEj is associated with 
upregulation of IL-s production and NK activity (Baxevanis et 
al., 1993) . Isoflavones as antioxidants can increase 
glutathione peroxidase activity (Hendrich et al. , 1994) which 
inhibits prostaglandin production (Marshall et al., 1988), and 
may also enhance IL-s production and NK activity. Data from 
our glutathione peroxidase activity and prostaglandin assays 
will clarify the role of these factors in mediating isoflavone 
effects. 
On the other hand, genistein can inhibit activation of NK 
cell by specifically blocking tyrosine kinase activity. NK 
cell activation is dependent upon the stimulation of cell 
surface receptors and proper regulation of intracellular 
second messengers. The activation of protein tyrosine kinase 
after the binding of NK receptors with IL-2, IFN-a, CD16, or 
tumor cell receptors is crucial step for NK cell activation 
(Borrego et al. , 1993) . Inhibitors of tyrosine kinase such as 
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genistein (at 20-110 |1M) can inhibit NK cell activity (Gerosa 
et al., 1993 ; O'Shea et al., 1992) . However, genistein plasma 
concentrations from physiologically achievable amounts of soy 
food consumption does not reach the inhibitory level based on 
extensive human bioavailability data collected by our 
laboratory. Our data from this study further indicated that 
genistein from physiological amount of soy food intake will 
not cause the suppression of NK activity in humans. 
In addition to exogenous factors, some endogenous 
hormones such as glucocorticoids have many immunosuppressant 
effects, which can reduce the release of various interleukins 
and suppress NK activity (Hadley 1993) . Because plasma 
glucocorticoid concentration varies diurnally, its level at 
1400-1500 h when subjects had their post-feeding blood draw is 
about 100 % higher than that in early morning pre-feeding 
blood draw. This difference of glucocorticoid concentrations 
may be one of the reasons why there was no significant 
difference in NK activity before and after one week soy milk 
feedings. In addition, Nilsson and Carlsten (1994) reported 
that estradiol reduced NK cell cytotoxicity at ®^Cr- release 
assay with YAC-1 cells as target cells in a dose-dependent 
manner. Among males and females of six mouse strains, 
estrogen suppressed NK activities by 25-80% compared with 
sham-treated controls after subcutaneous implantation of 5-mm 
long siliac tube packed with 2.5 mg 17p-estradiol benzoate for 
4 weeks. These may explain why female subjects had lower 
average pre- and post-feeding NK activities than male subjects 
although the difference was not statistically significant. 
Furthermore, although isoflavones may be antiestrogenic, they 
do not seem to be able to relieve the suppression of NK cell 
activity by endogenous estrogens in female subjects after 
seven days of soy milk consumption. Neither do isoflavones in 
the doses given down-regulate NK activity, even though they 
may inhibit tyrosine kinase activity. Further study is 
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essential to characterize the mechanism for modulation of NK 
cell activity by isoflavones. 
Literature cited 
Adlercreutz, H., Honjo, H., Higashi, A., Fotsis, T., 
Hamalainen, E., Hasegawa, T., and Okada, H. (1991) Urinary 
excretion of lignans and isoflavonoid phytoestrogens in 
Japanese men and women consuming a traditional Japanese 
diet. Am. J. Clin. Nutr. 54: 1093-1100. 
Adlercreutz, H., Goldin, B.R., Gorbach, S.L., Hockerstedt, 
K.A.V., Watanabe, S., H&tialainen, E.K., Markkanen, M.H., 
Makela, T.H., Wahala, K.T., Hase, T. and Fotsis, T. (1995) 
Soybean phytoestrogen intake and cancer risk. J. Nutri. 
125: 757S-770S. 
Barnes, S. (1995) Effect of genistein on in vitro and in vivo 
models of cancer. J. Nutr. 125: 777S-783S. 
Barnes, S., Grubbs, C., Setchell, K.D., and Carlson, J. (1990) 
Soybeans inhibit mammary tumors in models of breast 
cancer. Clin. Biol. Res. 347: 239-253. 
Baxevanis, C.N., Reclos, G.J., Gritzapis, A.D., Dedousis, 
G.V.Z., Missitzis, I. and Papamichail, M. (1993) Elevated 
prostaglandin E2 production by monocytes is responsible 
for the depressed levels of natural killer and lymphokine-
activated killer cell function in patients with breast 
cancer. Cancer. 72: 491-501 
Borrego, P., Pena, J. and Solana, R. (1993) Regulation of CD69 
expression on human natural killer cells: Differential 
involvement of protein kinase C and protein tyrosine 
kinases. Eur. J. Immunol. 23: 1039-1043. 
Cunnick, J.E., Lysle, D.T., Armfield, A. and Rabin, B.S. 
(1988) Shock-induced modulation of lymphocyte 
responsiveness and natural killer cell activity; 
differential mechanisms of induction. Brain Behav Immun. 
126: 278-289. 
Earnest, D.L., Hixson, L.J. and Alberts, D.S. (1992) Piroxicam 
and other cyclooxygenase inhibitors: Potential for cancer 
chemoprevention. J. Cell Biochem.,Suppl 161: 156-166. 
119 
Fotsis, T., Pepper, M., Adlercreutz, H., Flerischmann, G., 
Hase, T., Montesano, R. and Schweigerer, L. (1993) 
Genistein, a dietary-derived inhibitor of in vitro 
angiogenesis. Proc. Natl. Acad. Sci. USA. 90: 2690-2694. 
Gerosa, F., Tommasi, M., Benati, C., Gandini, G., Libonati, 
M. , Tridente, G., Carra, G. and Trinchieri, G. (1993) 
Differential effects of tyrosine kinase inhibition in CD69 
antigen expression and lytic activity induced by rIL-2, 
rIL-12, and rIFN-CX in human NK cells. Cell Immunol. 150: 
382-390. 
Hadley, M.E. (1994) Endocrinology, 3rd ed. Prentice Hall, 
Englewood Cliffs, New Jersey. 
Hendrich, S., Lee, K.W., Xu, X., Wang, H.J., and Murphy, P.A. 
(1994) Defining food components as new nutrients. J. Nutr. 
124: 1789S-1792S. 
Herberman, R.B. (1989) Natural killer cells. In: Natural 
Immunity (Nelson D.S., ed.), pp.71-122. Academic Press, 
San Diego, CA. 
Higashi, K. and Ogawara, H. (1992) Effects of isoflavone 
compounds on the activation of phospholipase C. Chem. 
Pharm. Bull. 40: 157-160. 
Kunkle, S.L., Chensue, S.W., Fantone, J.C. and Ward, P.A. 
(1984) Role of prostaglandins in macrophage cell function. 
In: The reticuloendothelial system. Vol 6 Immunology 
(Bellanti, J.A. and Herscowitz, eds.), pp.289-301. Plenum 
Press, New York, NY. 
Lundh, T.J.O., Pettersson, H., and Kiessling, K.H. (1988) 
Liquid chromatographic determination of the estrogens 
daidzein, formononetin, coumestrol, and equol in bovine 
blood plasma and urine. J. Assoc. Off. Anal. Chem. 71: 
938-941. 
Marshall, P., Kulmacz, R.J. and Lands, W.E.M. (1988) 
Constraints on prostaglandin biosynthesis in tissues. J. 
Biol. Chem. 262(8): 3510-3517. 
Matsui, M. and Watanabe, H.K. (1982) Developmental alteration 
of hepatic UDP-glucuronosyltransferase and 
sulphotransferase towards androsterone and 4-nitrophenol 
in Wistar rats. J. Biochem. 204(2): 441-447. 
120 
Meerman, J.H., Nijland, C. and Mulder, G.J. (1987) Sex 
differences in sulfation and glucuronidation of phenol, 4-
nitrophenol and N-hydroxy-2-acetylaininofluorene in the rat 
in vivo. Biochem. Pharmacol. 36(16): 2605-2608. 
Nilsson, M. and Carlsten, H. (1994) Estrogen induces 
suppression of natural killer cell cytotoxicity and 
augmentation of polyclonal B cell activation. Cellular 
Immuno. 158: 131-139. 
Ohnishi, H., Lin, T.H., Nakajima, I. and Chu, T.M. (1991) 
Prostaglandin E2 from macrophages of murine splenocyte 
cultures inhibits the generation of lymphokine-activated 
killer cell activity. Tumor Biol. 12: 99-110. 
O'Shea, J.J., McVicar, D.W., Kuhns, D.B. and Ortaldo, J.R. 
(1992) A role for protein tyrosine kinase activity in 
natural cytotoxicity as well as antibody-dependent 
cellular cytotoxicity: Effects of herbimycin A. Immunol. 
148: 2497-2502. 
Singer, S.S., Federspiel, M.J., Green, J., Lewis, W.G., 
Martin, V., Witt, K.R. and Tappel, J. (1982) Enzymatic 
sulfation of steroids. XV. Studies differentiating between 
rat liver androgen, estrogen, bile acid, glucocorticoid 
and phenol sulfotransferases. Biochim. Biophys. Acta. 
700 (1) : 110-117. 
Wang, H.J., and Murphy, P.A. (1994) Isoflavone content in 
commercial soybean foods. J. Agric. Food Chem. 42: 166 6-
1673 . 
Wei, H., Bowen, R., Cai, Q., Barnes, S. and Wang, Y. (1995) 
Antioxidant and antipromotional effects of the soybean 
isoflavone genistein. Proceedings of the Society for 
Experimental Biology and Medicine. 208(1): 124-130. 
Whiteside, T.L. and Herberman, R.B. (1989) The role of natural 
killer cells in human disease. Clinical Immun. Immunopath. 
53: 1-23. 
Wiltrout, R.H. and Hornung, R.L. (1989) Natural products 
antitumor agents: direct versus indirect mechanism of 
activity of flavonoids. J. of the Natl. Cancer Inst. 80: 
2 2 0 - 2 2 2  .  
Xu, X., Wang, H.J., Murphy, P.A., Cook, L., and Hendrich, S. 
(1994) Daidzein is a more bioavailable soymilk isoflavone 
than is genistein in adult women. J. Nutr. 124: 825-832. 
121 
Xu, X., Harris, K., Wang, H-J., Murphy, P.A. and Hendrich, S. 
(1995) Bioavailability of soybean isoflavones depends upon 
gut microflora in women, in press. 
122 
Table 1. Nutritional Analysis of Day 6 and 7 in Men and Women 
Day 6 Day 7 




Total Fat (g) 




Dietary Fiber (g) 
Insoluble Fiber (g) 
: g )  
: g )  
1887 ± 15.6 
84.4 ± 6.7 
258 .2 + 5.0 
53.8 ± 5.6 
20.5 ± 2.8 
21.2 ± 3.1 
10.4 ± 1.3 
125.1 ± 8.5 
15.5 ± 2.0 
10.0 ± 2.1 
2115 ± 20.1 
94.9 + 7.9 
292.3 ± 6.1 
60.4 ± 4.9 
23.0 ± 2.2 
25.5 ± 3.5 
10.2 ± 1.2 
123.0 ± 10.; 
17 .3 ± 2.4 
11.9 ± 3.0 




Total Fat (g) 




Dietary Fiber (g) 
Insoluble Fiber (g) 
Female 1.6 mg/kg (n=8i 
i g )  
: g )  
2092 ± 18.9 
90 .4 ± 7.2 
310.1 ± 6.4 
52.3 ± 5.1 
19.5 ± 2.3 
20.2 ± 2.6 
9.0 ± 0.9 
130.9 ± 8.1 
16.2 ± 2.7 
11.3 ± 2.5 
2034 ± 15.1 
87.9 ± 6.7 
282.3 ± 5.3 
60.1 ± 4.5 
25.2 ± 2.4 
23 .1 ± 3.1 
10.0 ± 1.1 
134.7 + 8.9 
16.9 ± 2.1 




Total Fat (g) 




Dietary Fiber (g) 
Insoluble Fiber (g) 
: g )  
! g )  
2007 ± 19.3 
90.0 ± 4.2 
274.2 ± 5.3 
60.7 ± 5.9 
24.5 ± 3.0 
25 .2 ± 3.4 
9.4 + 1.1 
129 .3 ± 8.9 
17 . 0 ± 2.9 
10 .4 ± 2.3 
2022 ±12.1 
89.5 ± 3.7 
285.7 ± 5.6 
57.4 ± 4.0 
21.7 ± 2.0 
23 .5 ± 3.3 
11.2 ± 1.5 
119.2 ± 8.1 
18.5 + 3.1 
12.7 ± 3.3 




Total Fat (g) 
( g )  
2612 ± 27.0 
119.3 ± 10.3 
337.1 ± 13 . 6 
85.7 ± 10.3 
continued 
2227 ± 18.4 
100.5 ± 7.5 
304.6 ± 8.9 
65.1 ±7.0 
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Dietary Fiber (g) 
Insoluble Fiber (g) 




Total Fat (g) 




Dietary Fiber (g) 
Insoluble Fiber (g) 




Total Fat (g) 




Dietary Fiber (g) 
Insoluble Fiber (g) 
continued, Table 1 
29.5 ± 4.4 22.1 ± 3 .1 
[g) 28.1 ±5.1 25.9+4.0 
Ig) 23.5 ± 2.8 15.4 ± 1.5 
191.2 ± 9.1 182.4 ± 11.7 
23 .3 ± 4.0 20.5 ± 3 .0 
17.3 ±3.6 15.2 ±2.9 
2481 ± 22.6 
116.2 ± 9.1 
327.5 ± 12.3 
75.6 ± 8.0 
26.5 ± 3.7 
(g) 25.2 ± 4.3 
(g) 21.0 ± 3.2 
188.5 ± 10.3 
22.7 ± 4.2 
16.1 ± 3.3 
2384 ± 20.6 
102.4 ± 8.0 
314.0 ± 9.4 
12.Q ± 8.4 
25 .8 ± 3.3 
26.0 ± 4.2 
18.3 ± 2.2 
176.2 ± 9.6 
21.9 ± 3.5 
14.8 ± 2.1 
2504 ± 24.5 
110.0 + 8.5 
366.9 ± 15.2 
66.1 ± 7.1 
24 . 9 ± 2.8 
(g) 23.3 ± 3 .5 
(g) 18.0 ± 2.8 
174.6 ± 8.5 
25.4 ± 6.0 
18.2 ± 5.2 
2352 ± 19.3 
107.4 ± 8.1 
324.2 ± 10.6 
69.3 ± 7.0 
23 .2 + 3.0 
25.8 ± 3.8 
17 .4 ± 2.0 
180.8 ± 9.9 
22.1 ± 3.8 
15.9 ± 2.5 
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Mai Daidzin 176 
Mai Genistin 625 
Mai Glycitin 62 
Ac Daidzin 247 
Ac Genistin 497 




Total Daidzein 572 
Total Genistein 1250 
Total Glycitein 102 
Values were the means (n=3). ND = Not Detectable. 
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Table 3. Plasma concentrations of isoflavones 6.5 h after 
7th day soy milk feeding 
Dosages 0 mg/kg 0. 8 mg/kg 1. 6 mg / kg 
|iM 
Female (n=8) 
Daidzein 0 . 08±0 , .04 1. 33±0.44 2 . 36±1.15 
Genistein 0 . 04±0 , .04 1. 48±0.49 2 . 47±0.91 
Equol ND^  0 .16±0.12 0 .27±0.12 
Male (n=8) 
Daidzein 0 . 04±0 .02 2 . 52±0.69^ 3 . 56±0 .79' 
Genistein ND 1. 98 + 0 .74 2 . 9410.80 
Equol ND 0 . 16+0.11 0 , .33±0.21 
^Significantly greater than that in females (p<0.01) by 
using ANOVA (GLM) with mean square for subjects within the 
same gender as the error term, 
^ND= Not detectable. 
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Table 4. Natural killer cell activity at pre- and 
post- feeding 
Pre-feeding Post-feeding 
Effector to target ratio = 50:1 
0 mg/kg 
Female (n=8) 37.6±5.4 44.8±7.3 
Male (n=8) 44.0±5.3 53.1+7.5 
0.8 mg/kg 
Female (n=8) 41.0±7.2 41.8±7.4 
Male (n=8) 47.1 ± 4.0 52.3 ± 7.2 
1.6 mg/kg 
Female (n=8) 40.8±7.5 41.9±7.4 
Male (n=8) 41.7 ± 6.7 53.4 ± 7.8 
Effector to target ratio = 25:1 
0 mg/kg 
Female (n=8) 23.015.1 29.6±5.7 
Male {n=8) 29.2 ± 6.7 38.5 ± 7.8 
0.8 mg/kg 
Female (n=8) 26.9+9.4 30.2±8.4 
Male (n=8) 29.5 ± 5.1 36.1 ± 7.0 
1.6 mg/kg 
Female (n=8) 28.3 ± 7.0 32.5 ±10.0 
Male (n=8) 26.4 ± 7.1 38.1 ± 9.2 
Effector to target ratio = 12.5:1 
0 mg/kg 
Female (n=8) 12.2 ± 9.9 16.9 ±12.0 
Male (n=8) 18.4 ±15.4 21.1 ±12.0 
0.8 mg/kg 
Female (n=8) 17.6 ±15.2 18.5 ±15.7 
Male (n=8) 16.5 ±11.8 17.9 ± 9.2 
1.6 mg/kg 
Female (n=8) 15.2 ±13.8 18.6 ±17.8 
Male (n=8) 16.2 ±14.4 20.8 ±12.2 




0 mg/kg 0.8mg/kg 1.6 mg/kg 
Day Seven 










0.30±0.38 7.92+2.34 15.36±3.85 
0.04±0.05 3.22±1.55 6.99±2.38 
ND 0.54±0.49 1.01±0.75 
0.16+0.19 13.19±4.57i 24.04±4.22^ 
0.02±0.06 5.30±2.95 8.98±3.66 



















^Significantly greater than that in females (p<0.01) by using ANOVA (GLM) with 
mean square for subjects within the same gender as the error term. 
^For both male and female subjects, urinary daidzein was significantly greater 
than genistein and equol in each of last two soy feeding days (p <0.01). 
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Table 6. Total fecal isoflavone excretion at last two days of 
one week soy milk feeding^ 
Dosages 0 mg/kg 0 . 8 mg/kg 1, .6 mg/kg 
mg 
Female (n=8) 
Daidzein 0.03±0.04 1, ,44±1. 00 3 . 02±1.80 
Genistein 0.03±0.07 1. 28±0. 89 3 . 03±2.76 
Equol ND 0 . ,34±0, .20 0, .49±0.31 
Male (n=8) 
Daidzein 0.03±0.04 1, .45±0, .43 3 , .12+1.28 
Genistein 0.03x0.04 1 .18±0 .36 3 .17±1.35 
Equol ND 0 .29±0 .19 0 .51±0.28 
^The amounts of fecal isoflavone excretion were not 
affected by sex or type of isoflavones (p>0.1) but the dosage 
(p<0.05) in ANOVA (GLM). 
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SUMMARY 
Our studies indicated that h\iinan absorption and excretion 
of isoflavones from soybean and soy foods are dose-dependent. 
Daidzein is a more bioavailable soy isoflavone than is 
genistein as reflected in urinary recovery of ingested 
isoflavone. 
Gut bacteria play a important role in determining the 
pattern and magnitude of soy isoflavone absorption and 
degradation. Modulation of gut bacteria may provide 
additional means to optimize soy isoflavone bioavailability 
and potential health protective effects. 
Variation of protein and fat content in background diets 
had little effect on isoflavone bioavailability reflected in 
their urinary recovery. Different soybean foods containing 
various amounts of isoflavone conjugates and aglycones did not 
change human bioavailability pattern and magnitude. These 
results suggested that ad libitum diet may be appropriate in 
the future short-term human soy isoflavone feeding studies. 
Isoflavones can reach steady state in shorter than five 
days of continuous soy milk feeding. Disposition pattern of 
isoflavones in this one-week feeding study showed sex-related 
difference with greater amounts of urinary excretion and 
higher plasma concentration of daidzein in male subjects than 
in female subjects. There was no significant difference in 
NK activities between different sex, dosages as well as pre-
and post-soy milk feeding. Further well-controlled 
experiments are essential to prove the hypothesis that 
isoflavones can increase NK activity by inhibition of 
prostaglandin synthesis in monocytes. 
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